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ABSTRACT OF DISSERTATION 
 
 
 
 
TARGETED POLYMERIC BIOMATERIALS FOR THE PREVENTION OF POST 
SURGICAL ADHESIONS 
 
Despite recent advances in surgical technique and the development of numerous 
therapeutic agents, the formation post surgical adhesions (PSA) continues to cause 
complications for many patients. In this research, we have employed a rational system to 
develop a novel treatment to address this clinical need. Based on an understanding of the 
biochemical events that lead to PSA formation, a series of targeted polymeric 
biomaterials was designed to interrupt the fibrin gel matrix propagation and suppress 
PSA formation.  
Using group transfer polymerization, a series of well controlled block copolymers 
of polyacrylic acid and poly(ethylene glycol-methacrylate) based materials was 
synthesized. Subsequent functionalization with the pentapeptide Cys-Arg-Glu-Lys-Ala 
(CREKA) was employed to target the materials to fibrin as a marker of pro-adhesive 
sites. While preliminary testing of the untargeted materials verified their ability to 
suppress non-specific protein adsorption to model surfaces, numerous in vitro tests were 
conducted to study the ability to inhibit fibrin gel propagation. The ability to inhibit both 
the rate and quantity of fibrinogen deposition to a fibrin coated surface has been 
demonstrated. In addition, the rate of fibrin gel propagation and the degree of cellular 
attachment can modulated.   
Taking advantage of the systematic variation in structure facilitated by the robust 
synthetic methodology employed, statistical analysis was used to elucidate the structure-
property relationships governing the performance of these materials. The most important 
factors that lead to enhanced performance in in vitro tests are the length of PEG chain and 
number of peptide units conjugated to the polymer: increasing PEG chain length and 
increasing the number of peptides conjugated to the polymer both improve performance 
in all tests. The synthetic methods that have been developed, in conjunction with the 
experimental results, will be used to direct future studies, including cytotoxicity and 
animal studies. 
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CHAPTER 1. INTRODUCTION 
 
Post-surgical adhesions (PSA), abnormal fibrous linkages between adjacent tissue 
surfaces, represent one of the most common and significant complications facing surgical 
recovery today.  It is believed that the vast majority of surgical patients experience this 
complication [1-2]. While, in most cases, these adhesions are not problematic, many 
patients require subsequent treatment(s) to correct the complications that arise. 
Approximately 440,000 adhesiolysis procedures are performed each year in the United 
States at an estimated total cost of over $1 billion [3-4]. Numerous strategies have been 
investigated to reduce adhesion formation, including changes in surgical technique and 
the development of adhesion barrier strategies. Unfortunately, no method has yet been 
devised that provides general applicability and affords adequate protection.  
In this research, we have developed a new targeted polymeric material designed 
to address this problem by assembling at pro-adhesive sites and providing protection 
against PSA formation. The preliminary data contained herein suggest that this material 
may provide a novel approach to the prevention of post surgical adhesions. In vitro 
studies have demonstrated the ability of these synthetic polymeric materials to assemble 
onto model surfaces and prevent the early steps (e.g., protein absorption, fibrin growth, 
cellular attachment) in the event cascade that leads to PSA formation.  
A rational design approach was used to identify the molecular properties that can 
be used to engineer a potential treatment to meet a specific medical condition. Based on 
the physiology and pathology of post surgical adhesion formation, polymeric materials 
were designed to interact with the fibrin gel matrix and suppress its development. These 
polymers incorporated peptide targeting units to control the interactions with fibrin and 
 2 
 
polyethylene glycol units to form a surface layer that resists subsequent fibrin deposition. 
Preliminary testing demonstrated the viability of the concept, while more thorough 
experiments confirmed the ability to modulate the series of biochemical events that lead 
to adhesion formation. As anticipated, the structure of the polymer employed exerts 
dramatic influence on the ability of these materials to function as designed. Based on the 
encouraging results obtained from these experiments, in vivo studies are planned to assess 
the function of these materials in a rabbit model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © John M. Medley 2010 
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CHAPTER 2. BACKGROUND 
 
Based on review published in:  
Biological Interactions on Materials Surfaces Understanding and 
Controlling Protein, Cell, and Tissue Responses Puleo, David A.; Bizios, 
Rena (Eds.) 2009 [5]. Used with permission. 
 
2.1. Problem Statement 
Each year in the United States, millions of people submit themselves to 
abdominal surgery for a variety of reasons, including gynecological reconstruction, tumor 
removal, and Cesarean sections [1-2]. While the success rate and recovery times for the 
initial surgeries are continually improving, complications frequently occur. One major 
complication of abdominal surgery, occurring in the vast majority of patients, is the 
formation of tissue adhesion. While it is impossible to determine the incidence rate with 
certainty, several studies indicate that post surgical adhesion formation occurs in 65 – 
97% of abdominal surgery patients [1-4]. This acellular, collagen rich tissue often forms 
when an organ is damaged due to inadvertent desiccation or trauma during surgery. 
During healing, this damaged tissue often becomes permanently attached to adjacent 
tissues by the formation of a fibrous scar, as shown in Figure 2-1. While the nearly 
ubiquitous formation of adhesions is not generally problematic, numerous problems can 
arise that require subsequent physician care. Many patients experience abdominal or 
pelvic pain, intestinal obstructions, infertility, and increased difficulty in subsequent 
surgical procedures.  In addition to the immeasurable costs in patient pain and suffering, 
an estimated 440,000 adhesiolysis procedures are performed in the United States each 
year [3-4].  
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2.2. Post-surgical Adhesion (PSA) Formation 
The mechanism of these formations has been shown to follow the same basic 
pathway as intraperitoneal wound healing. The cells, proteins, and tissues involved in this 
mechanism, which have been described in numerous review articles, are shown 
graphically in Figure 2-2 and can be summarized as a sequence of eight steps, as 
described in Table 2-1 [6-8]. When this process initiates on an open surface, typical 
wound healing is observed, including the associated scar tissue formation. If an opposing 
surface is bridged by the Fibrin Gel Matrix (FGM) (see Table 2-1, step 6), the resulting 
scar tissue can permanently connect these surfaces, resulting in the formation of post 
surgical adhesions. 
Depending where these adhesions form, a variety of complications are possible. If 
the adhesions involve the intestines, bowel obstructions can result [9-11]. In female 
patients, adhesions can obstruct the fallopian tubes and result in reduced fertility [9, 12-
13]. Following surgery, many patients experience abdominal pain, which is believed to 
be a result of reduced mobility of the organs within the abdominal cavity [9, 12, 14-15]. 
Finally, subsequent surgeries can be complicated as tissue adhesions may interfere with 
the surgeon’s access to organs [16-17]. Adhesions also form in areas of the body outside 
of the abdominal cavity. Numerous medical specialties, including cardiosurgery, 
neurosurgery, and orthopedic surgery, are plagued by the formation of complications 
arising due to postsurgical adhesion [18-23]. 
The costs associated with PSA in the United States are substantial. Approximately 
300,000 hospital readmissions annually are either directly or indirectly related to the 
formation of PSA; the annual financial expenditure for pertinent treatment costs exceeds 
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$1.3 billion [3, 8]. Based on the significant financial costs and the immeasurable cost in 
terms of patient discomfort, the need either to eliminate or reduce the incidence and 
severity of PSA is apparent. 
2.3. Methods of PSA Prevention and Control 
Based on the well-characterized PSA formation mechanism, researchers and 
physicians have developed numerous approaches to prevent their formation. These 
approaches can be classified into four general categories: modification of surgical 
technique, pharmaceutical approaches, liquid instillates, and adhesion barriers. While 
none of these techniques can eliminate the incidence of PSA completely, each approach 
has demonstrated encouraging results, with research continuing along all four directions. 
2.3.1. Modification of Surgical Technique 
Since PSAs are known to form as the result of tissue trauma, it is logical that the 
number and severity of PSA can be reduced by reducing the trauma to tissues during 
surgery. Simple changes, such as implementing the use of non-powdered surgical gloves, 
can reduce desiccation of the peritoneum and have a positive impact. During open 
abdominal surgery, the peritoneum is often sutured closed to aid healing. This practice 
increases the length of surgery and, since the peritoneum is known to heal rapidly via 
island implantation, it has recently been questioned [24-26]. Several studies have recently 
been conducted to assess the necessity of suturing the peritoneum and its affect on the 
formation of PSA; the results have been mixed [1-2, 13, 24-26]. As described in Section 
2.5, the presence of suture materials can induce an exacerbated wound healing response, 
due to the foreign body reaction, and promote PSA formation [27].  
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Another common surgical procedure, installation of prophylactic drainage tubes 
following abdominal surgeries, has also been a subject of investigation [28]. Often 
performed as an effort either to remove excess serum and blood (to reduce infection) or 
to provide an early warning of surgical complications, the necessity of this technique is 
uncertain [29-32]. In fact, the presence of drainage tubes can increase the likelihood of 
infection following abdominal surgery and has been shown to increase the incidence of 
PSA [31].  
Recent investigations suggest that increasing the oxygenation of tissues in the 
abdominal cavity may affect the biochemistry of the wound healing process. Reduced 
oxygen levels in tissue (e.g., due decreased blood flow) can reduce the ratio of tissue 
plasminogen activator (tPA) to plasminogen activator inhibitor-1 (PAI-1) present in that 
tissue [33]. Since plasmin is necessary to break down the fibrin gel matrix (see Table 
2-1, step 6), this reduced oxygen level may contribute to increased PSA formation. 
Oxygenating tissues during surgery has demonstrated some success at reducing the 
impact of PSA [33]. 
Since PSA is a result of trauma to the internal organ surfaces, reductions in the 
incision size, shortening the time of surgery and the overall invasiveness of the procedure 
should result in a reduction of PSA.  Indeed, laparoscopic surgical methods have resulted 
in a major reduction in the incidence and severity of PSA [34-36]. Unfortunately, not all 
surgeries, such as gynecological reconstruction or emergency procedures, are amendable 
to laparoscopic methods. In addition, even though the incidence of PSA is reduced, 
laparoscopy can result in some tissue trauma with PSA formation still a likely outcome. 
Implementation of improved surgical procedures, while effective at reducing the 
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incidence and severity of adhesions, does not eliminate the risk of PSA formation. A 
significant clinical need still exists for alternative interventions to inhibit PSA formation.  
2.3.2. Pharmaceutical Interventions 
Since PSA formation is a product of uncontrolled wound healing, by 
pharmacologically intervening in this process, it may be possible to reduce the effect of 
pathways leading to tissue adhesions. However, implementation of these techniques has 
been frustrated by the complex biochemical nature of the wound healing process. For 
example, while it may be desirable to modify the healing process at the site of basement 
membrane exposure, biological approaches can potentially disrupt the beneficial healing 
throughout the body, resulting in more severe post-surgical complications. 
Initial attempts to employ pharmaceutical agents focused on the reduction of 
tissue trauma. Local application of anti-inflammatory medications (i.e., ibuprofen, 
steroids, antihistamines, etc.) has been used to reduce inflammation at the surgical site. 
Interestingly, these therapies have demonstrated some efficacy during preclinical trials at 
reducing the formation of PSA [37-38]. This result is likely due to the understood link 
between excessive inflammation and fibrosis [39]. 
Similarly, attempts at mitigating oxidative stress at the wound site have also been 
employed to suppress the formation of PSA.  While generation of oxygen radicals 
(typically from the leukocyte respiratory burst) [40-41] is a necessary part of the wound 
healing cascade, an excessive amount is known to activate collagen producing cells 
resulting in exaggerated levels of fibrosis [42-43]. It is logical to expect, then, that 
administration of antioxidant molecules would suppress formation of collagen rich tissues 
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[44]. Melatonin, vitamin E, and catalase have all shown some promise in reducing the 
severity of post surgical adhesion formation [44-47].  
Heparin, a naturally occurring anticoagulant, interrupts various steps of the 
coagulation cascade and inactivates thrombin. Used to treat numerous pathologies and to 
create biologically-passivated surfaces, heparin has been investigated as an agent to 
reduce PSA formation. The results of these investigations, however, have been 
disappointing [48]. 
The most beneficial pharmaceutical interventions have employed fibrinolytic 
agents to reduce PSA formation. These enzymes, occurring naturally in the body, play a 
key role in the degradation of blood clots. As a result of trauma caused by surgery, 
production of these enzymes is suppressed [49-50]. It was proposed that the formation of 
PSA can be prevented by accelerating the degradation of fibrin deposits with locally 
delivered fibrinolytic agents to break down the fibrin gel matrix (FGM). This adhesive 
fibrin gel matrix is responsible for the formation of the initial deleterious union of 
adjacent tissue surfaces.  Early investigations involved treatment with bacterially-derived 
streptokinase,  a protein that catalyzes formation of plasmin which, in turn, breaks down 
the fibrin mesh of blood clots [51]. Increased plasmin activation proved beneficial in both 
animals and in humans and resulted in the commercialization of “Varidase” in the 1970s 
[52-54]. Additional investigations used the plasminogen activator enzyme, urokinase, and 
plasmin directly via intraperitoneal injection; mixed results and potentially immunogenic 
responses were observed [55-56]. Despite these inconsistencies, direct management of 
fibrin, the primary adhesive protein, represents an attractive PSA prevention strategy. 
Recent studies, focusing on the use of recombinant tissue plasminogen activator (rt-PA) 
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demonstrated significant potential to successfully address PSA formation [50]. While the 
use of tissue plasminogen activators has shown efficacy in reducing the incidence of PSA 
formation, they have been shown to increase the risk of hemorrhage in many applications 
[2, 57-58].  
Oral delivery of drugs to reduce PSA formation has recently been investigated 
[59]. Chymases, naturally occurring proteases, stimulate accumulation of neutrophils and 
other inflammatory cells at the trauma site; these enzymes cleave procollagen into 
collagen fibrils, a primary step in the formation of the collagen rich tissue bridge.  It was 
hypothesized that, by inhibiting/slowing the formation of collagen fibrils, the FGM could 
break down before PSA formation can occur. A recent study employed oral delivery of 
NK3201, a novel chymase inhibitor, showed significant reduction in chymase activity 
and, thereby, suppressed PSA formation in a hamster model [59]. 
2.3.3. Liquid Instillates  
During surgery, saline solution is typically instilled into the body cavity to 
accomplish a number of goals. In addition to maintaining a clean surgical site (by 
removing blood and other biological debris), this solution also maintains hydration of 
exposed tissues. In an effort to reduce PSA formation, several alternate liquid instillates 
have been investigated.    
Hyaluronic acid (HA), whose chemical structure is shown in Table 2-2, is a 
naturally-occurring biological polymer consisting of a long chain of disaccharide units 
with a molecular weight that can exceed 20 million Daltons. HA is a principal component 
of the extracellular matrix of tissues throughout the human body. HA can readily be 
broken down into its principle sugar molecules and metabolized within the body; these 
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degradation units, both monomeric and oligomeric, are potent signals for macrophage 
and cell recruitment, angiogenesis, and the presumed non-scarring, fetal-like, wound 
healing response [60-63]. Because of these properties, the use of HA has been 
investigated as a means to reduce PSA formation. If instilled prior to surgery, HA can 
effectively coat the organs in the abdominal cavity and provide protection against 
surgical trauma and tissue desiccation [64-65]. HA reduces the tissue adhesion score to 
0.9 ± 1.1 versus 2.0 ± 0.8 obtained from the controls in a mouse model and has been 
approved for use by the FDA [64].  
Several chemical modifications of HA have been formulated in order to improve 
its in vivo performance. By slowing HA degradation kinetics, it is believed that additional 
protection against PSA formation can be obtained. HA crosslinked with ferric ion 
(FeHA) reduced adhesion scores by 59% in clinical trials and led to the commercial 
product “Intergel” [66-67]. This product was withdrawn from the market after reports of 
additional complications, including pain and a foreign-body response attributed to the 
high iron content [48, 68]. By esterifying the hydroxyl groups on one HA chain with the 
carboxyl groups on another HA chain, it is possible to form an autocrosslinked HA 
derivative (HAx). This material forms a hydrogel and provides surface tissue protection 
for a longer duration. Tests in a rabbit model demonstrated the reduction in the adhesion 
score from 3.0 for controls to 0.5 in the treatment groups [69]. Clinical trials have also 
demonstrated reductions in adhesion scores of approximately 60% versus controls [70-
71]. In addition, it is not clear whether these esterfied HA monomers possess the same 
degree of chemotacticity as native HA and, thereby, alter the rate of cellular infiltration 
and wound healing at the surgery site [72]. 
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The most effective HA-derived liquid instillate employs crosslinked HA with 
another biologically-derived polymer, carboxymethylcellulose (CMC). CMC, whose 
structure is shown in Table 2-2, is a non-toxic material, used as a thickening agent in 
many food and drug products. CMC is not degraded in the body as rapidly as HA [69, 73-
74]. After partial oxidation, HA can be chemically crosslinked with CMC; this chemical 
combination of HA with CMC, which is commercially available as “Sepracoat,” results 
in an instillate with a residence time in the abdominal cavity of approximately seven days 
[66, 75-77]. This material has demonstrated significant protection against PSA formation 
in animal models but failed to convince the Federal Food and Drug Agency Panel of its 
clinical effectiveness against preventing adhesions in human patients [78].  
Liquid instillates based on the chemistry of phospholipids have also been 
employed. These materials, whose general chemical structure is shown in Table 2-2, are 
amphiphilic: they have a polar, hydrophilic head group and a hydrophobic tail. This 
amphiphilicity accounts for the surfactant properties exhibited by these materials; they 
adhere to hydrophilic surfaces and form a protective boundary lubricating layer with their 
hydrophobic tails extending from the surface [79]. Several amphiphilic lipids 
(phospholipids, sphingolipids, galactolipids), have been tested to reduce PSA formation 
and demonstrated significant potential to reduce PSA formation [80-82]. In a rabbit 
model, these materials reduced the area of adhesion formation from 691 mm2 to 191 mm2 
[80].  
Another class of materials has been designed to provide protection in the 
abdominal cavity without pretreatment via hydroflotation. The saline solutions typically 
used for irrigation during surgical procedures fall into this category. “Adept,” a 
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commercial product based on icodextrin, a polymeric starch, whose chemical structure is 
shown in Table 2-2, has been used for irrigation and rinsing during surgery [83]. After 
surgery, the polymeric starch is absorbed into the lymphatic system very slowly due to its 
high molecular weight [84]. Because of its high concentration, this material increases the 
osmotic pressure in the abdominal cavity and maintains an increased level of fluid [85]. 
The presence of this excess fluid results in tissue separation and has been shown to 
decrease PSA formation [84, 86-89]. In the rabbit dual uterine horn model, “Adept” 
increased the number of adhesion-free sites to 50% versus the 5% obtained for the 
untreated controls [84]. 
Polyethylene glycol (PEG), discussed in Section 2.5, has also been employed in 
efforts to reduce PSA formation.  This material, often referred to as polyethylene oxide 
(PEO), was proven biocompatible in a number of applications and is under investigation 
for a number of additional uses [90].  PEG, whose chemical structure is shown in Table 
2-2, consists of a series of repeating ether units with either hydroxyl or methoxy 
terminations at both ends.  This structure renders PEG amphiphilic and resistant to 
protein adsorption.  Soluble in many organic solvents, PEG is highly hydrophilic and can 
form a hydrated layer with a large excluded volume and high steric stabilization [90-91].  
PEG surfaces present few binding sites for protein interactions; for this reason, 
adsorption of proteins, and subsequent adhesion of cells, is strongly inhibited.  Injection 
of PEG into the peritoneal cavity has been moderately successful in preventing PSA 
formation [4].  Yet, because of their anti-adhesive nature, free PEG chains adhere poorly 
to surfaces. Attempts to increase the protective ability of PEG by crosslinking with CMC 
 13 
 
into a viscous gel have achieved a 42% reduction in the American Fertility Society 
adhesion score versus the relevant controls [92].  
A recent attempt to prevent PSA formation employed sequential use of solutions 
containing charged polypeptides [93]. A solution containing poly(L-lysine) (PLL) was 
instilled into the peritoneal cavity followed by a solution of poly(L-glutamate) (PLG) five 
minutes later. Positively-charged PLL, whose chemical structure is shown in Table 2-2, 
adheres to damaged tissues. Negatively-charged PLG, whose chemical structure is also 
shown in Table 2-2, associated with the positively-charged PLL on the surface and forms 
an insoluble film at the site of injury. In animal studies employing a mouse model, this 
system reduced the incidence of PSAs from 49.5% in the animals to 8.81% in treated 
animals [93-94]. Further implementation of these materials may be hampered because of 
toxicity concerns associated with the highly charged polyamines employed [93].   
2.3.4. Adhesion Barriers 
Currently, the most consistently effective methods that reduce the incidence and 
severity of PSA formation provide physical separation of wounded from surrounding 
tissues. By isolating damaged or potentially damaged surfaces from each other during the 
wound healing process, normal healing without the formation of PSAs was achieved [2, 
8]. Because of the simplicity and efficacy of this approach, numerous barrier systems 
have been investigated. 
The first adhesion barrier system investigated consisted of grafts of peritoneal 
tissue aimed at providing protection to areas of damaged peritoneum. The presence of 
necrotic graft material, however, promoted, rather than inhibited, PSA formation in 
animal trials [48]. Other attempts to protect tissues by stretching the nearby peritoneal 
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membrane also proved ineffective [48]. Decreased blood flow in this distorted tissue 
results in decreased plasmin activation and enhanced the formation of the fibrin gel 
matrix [48].  
Another material that has been investigated for use as an adhesion barrier is 
poly(tetrafluoroethylene) (PTFE) [95]. Because PTFE is known to resist adhesion to most 
substances, it is a natural candidate for use as a PSA barrier. This material, whose 
structure is shown in Table 2-2, consists of a straight chain of carbon atoms onto which 
fluorine atoms are fully substituted. The fluorine atoms present an inert, electron-rich 
surface that prevents strong interactions with other materials. PTFE is readily available as 
an expanded mesh, commonly referred to as ePTFE, under the trade name “Gore-Tex 
Surgical Membrane” [96-97].  The presence of PFTE between damaged tissue surfaces 
prevents the FGM from bridging these tissues and, thus, prevents PSA formation [3, 98-
101].  In animal tests employing a porcine model, PTFE reduced the adhesion score to 
0.14 ± 0.12 versus the observed 1.33 ± 0.41 for controls [101].  
The major drawbacks of PTFE result from its high degree of inertness. Since 
PTFE is so effective at preventing interactions with biological tissues, it typically must be 
sutured into place in the body [102]. In addition, PTFE is not biodegradable. Ideal for 
permanent prosthetic applications, the use of PTFE as an adhesion barrier can be 
problematic [99]. After the body has healed from the trauma induced by surgery, 
typically within about two weeks, the presence of the PTFE membrane at the site of 
trauma is undesirable. A second surgery, then, is typically necessary to remove this 
barrier material and ensure that unwanted complications are prevented [100]. 
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Several barrier membranes have been investigated that overcome this limitation of 
PTFE. Designed to be readily biodegradable, such membranes often do not need suturing 
into position and, thus, subsequent removal. After the desired protection has been 
rendered, these membranes break down and are metabolized by the body. Numerous 
biodegradable materials have been investigated for use as adhesion barriers, including 
cellulose derivatives, hyaluronic acid derivatives, and PEG-based materials [102-107].  
Oxidized regenerated cellulose (ORC) was employed to form a barrier that was 
successfully commercialized under the trade name “Interceed.” Cellulose, a naturally 
occurring polysaccharide, whose structure is shown in Table 2-2, is partially oxidized to 
improve aqueous solubility. This biodegradable material has a gauze-like consistency and 
can be applied directly to damaged tissues in order to prevent PSA. When properly 
applied, this material has shown a high degree of efficacy in reducing PSA formation in 
surgical procedures. There are, however, several limitations to the clinical use of 
“Interceed” [94, 99]. Because it is thrombogenic, contact with blood greatly increases the 
likelihood of subsequent surrounding tissue adhesion; because of this property, complete 
hemostasis must be achieved prior to in situ application of “Interceed.” In addition, 
application must be limited to a single layer of material in all areas; multiple layers may 
promote adhesions [48]. These difficult handling requirements render “Interceed” 
unsuitable for laparoscopic procedures and limit its general applicability to more invasive 
laparotomic procedures.  
Barriers based on HA crosslinked with CMC are available under the trade name 
“Seprafilm.” This material is applied as rigid sheets that, once hydrated, form a protective 
gel on the abdominal tissue surface and prevent PSA formation. With a chemical 
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composition nearly identical to “Sepragel,” this material is readily biodegraded in vivo 
within about one week. Provided that a surgeon has knowledge and access to all areas of 
tissue damage, “Seprafilm” can be very effective at preventing PSA formation [102-104]. 
In animal studies employing a rat model, the total adhesion score was reduced to 4.15 ± 
0.58 from 7.21 ± 0.52 obtained for the respective controls [77]. A meta-analysis of 
clinical data also demonstrated “Seprafilm” to be effective at lowering the incidence of 
PSAs in abdominal surgeries [108]. While this study mistakenly included a non-
“Sepracoat” HA/CMC material in its analysis, it reported that patients receiving the 
“Sepracoat” were 8.71-times more likely (p < 0.01) to have no adhesions than the control 
group (p < 0.01) [108]. While the rigid structure of “Seprafilm” has traditionally 
prevented its use in laparoscopic surgery, newer techniques involving the use of rolled 
films has provided some limited laparoscopic use [109].  
Since the number of procedures performed by laparoscopic surgery is continually 
increasing, the ability to apply antiadhesive therapies via this method is increasingly 
important. A material recently developed to address this clinical need is the two-
component system commercially available as “SprayGel.” This system consists of a 
double-barrel syringe used to apply the contents to damaged tissue via laparoscopy. Each 
barrel contains a reactive PEG precursor solution. Upon mixing, an amine group from 
one component reacts with N-hydroxysuccinimide (NHS) ester in the other component to 
form a crosslinked hydrogel, as shown in Table 2-2. This crosslinked material degrades 
in vivo into PEG units that are rapidly removed from the body by renal clearance [105-
106]. Since “SprayGel” is readily applicable in laparoscopic procedures, the major 
limitation for its use in PSA suppression is the surgeon’s awareness of, and access to, 
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damaged tissues. In clinical trials, this material showed significant efficacy because it 
reduced the mean adhesion tenacity score by 64.7% versus the values obtained for the 
untreated controls [110]. 
The aforementioned adhesion barriers have proven efficacious in reducing PSA 
formation in patients; for this reason, these commercially available products are enjoying 
success in the marketplace. Even with these methods, however, PSA formation is still 
occurring. For instance, in the 2007 meta-analysis of “Seprafilm” described earlier, of the 
371 patients in the adhesion barrier treatment group (combined over several studies), 196 
still had developed a post surgical adhesion [108]. With a prevention rate of only ~ 48%, 
multiple hypotheses have emerged to explain the persistent occurrence of PSA. If the 
surgeon is unaware of damaged tissue or if the damaged site is inaccessible, current 
barrier methods may not be effective and tissue adhesion formation remains a likely 
outcome. To overcome these deficiencies, many new strategies for the prevention of PSA 
are currently being investigated. Some of these investigations focus on combinations of 
techniques that have demonstrated success in the past. For example, various hydrogels 
have been loaded with either anti-inflammatory, antibiotic, or fibrinolytic agents, 
including budesonide, paclitaxel, or streptokinase [38, 46, 111-113]. In addition, changes 
to pertinent surgical technique are under investigation [31, 33, 59]. A brief summary of 
the most widely investigated PSA prevention methods is given in Table 2-3. 
2.4. PSA Evaluation Methods 
Perhaps one of the biggest impediments to the rapid development of PSA 
prevention strategies, especially to the testing of barrier materials, is the lack of a 
standard and widely used method to evaluate and compare pertinent performance. The 
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situation is complicated because various animal models are used and each clinical trial is 
conducted independently. Due to the complex interplay of the many facets of the wound 
healing process, inflammatory cascades, and anatomical aspects, in vivo studies are an 
integral part of PSA evaluation. Animal testing, however, is, by its nature, very complex, 
time consuming and limited in its ability to provide useful data comparisons among 
studies. In addition, large-scale screening of materials is not typically possible because of 
the associated high cost, time requirements, and ethical issues. Furthermore, in most 
animal models, failure of PSA treatment strategy does not always provide useful 
information regarding the underlying mechanism of failure. Methods of assessment have 
been primarily based on semi-quantitative animal models, including mouse, rat uterine 
horn, rabbit, and porcine; these models are summarized in Table 2-4. The results of such 
studies are typically scored based on visual observations (e.g., no adhesion, filmy 
avascular adhesion, vascularized adhesion, collagen rich adhesion) in an attempt to 
provide meaningful comparisons. Because of the large variability in the test methods and 
in data analysis, it is generally not possible to conduct meaningful comparisons between 
independent investigations. Results of material performance are often either confounded 
or obscured by the differences in the models and scoring systems employed. 
Furthermore, there has been a significant lack of translational relevance from in 
vivo PSA treatment models to clinical application and success. A strong need exists to 
revisit the fundamental aspects of adhesion formation and obtain more information 
regarding the underlying mechanisms for both the success and failure of each treatment. 
Recent attempts to address these issues have focused on standardizing the methods of 
testing and quantifying tissue adhesion formation. A grading system, described in Table 
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2-5, was developed to evaluate three characteristics (specifically, extent, severity, and 
degree) of adhesion formation; application of these three measures assigns a total 
adhesion score [114]. While still semi-quantitative, this grading system provides some 
quantitative information and allows comparisons to be made between the results of 
various studies.  
Most recently, complete quantitative investigations and in vitro models are being 
developed to allow for a rational optimization of potential treatments prior to large-scale 
animal tests. Investigators have reported preliminary results indicating that tissue 
adhesions can be reproducibly formed in a porcine model and analyzed using a tensile 
test system [115].  This tensile strength analysis method provides bulk modulus data of 
the formed scar tissue, allowing direct quantitative assessment of the quality and maturity 
of the adhesion and does not rely upon physical appearance alone [115].   
In order to overcome many of these limitations, a comprehensive understanding 
of the nature of the mechanism controlling the PSA reduction is highly desirable. This 
result can be achieved by developing reproducible in vitro tests and systematically 
studying the effects of various materials on the results. If this work can then be correlated 
with the results of in vivo studies, the relative importance of various in vitro tests can be 
assessed and development of additional PSA prevention strategies can be carried out in a 
much more systematic and efficient manner. 
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2.5. Biomaterials 
2.5.1. Background 
Over the past three decades, the medical field has benefitted greatly from 
numerous advances in material properties. Since the early 1980s, several definitions have 
been proposed to describe the field of biomaterials [116-118]. The main concepts that are 
generally regarded as important in designing a biomaterial are that something interact 
with the body in a desired manner and that it provide the desired function. One widely 
used definition of a biomaterial was promulgated in 1987: “A biomaterial is a nonviable 
material used in a medical device, intended to interact with biological systems” [119]. 
This broad field of study encompasses a wide array of materials and devices, ranging 
from simple disposable catheters and syringes to complex, permanently implanted 
devices such as artificial joints and pacemakers. Recent advances have enabled the 
development of increasingly complex biomaterial devices, such as those used for tissue 
engineering and artificial organs [118, 120-121]. As these devices have become more 
complex and permanent, understanding and controlling the interactions of the component 
materials with the body has become increasingly important. 
2.5.2. Biomaterial Interactions 
Consisting principally of cells, proteins, and extracellular matrix, natural tissue is 
a complex, active material.  Each component contributes unique functionality to the 
tissue, and the synergistic effect of these components creates a sophisticated composite 
system.  Conversely, typical synthetic biomedical implants consist of much more 
homogeneous materials that have been optimized for a particular function.  As a result, 
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implant materials are often inferior to natural tissues in many ways, including strength, 
elasticity, and capacity for self-repair.   
Another difficulty with biomaterials is that implants are rarely constructed from 
materials native to the patient.  When a biomaterial is implanted into the body, a complex 
series of biochemical events is triggered. Initially, the body’s response is focused on 
hemostasis. During the ensuing inflammatory phase, the body attempts to isolate or 
remove any injurious agents using its natural defenses. Depending on the nature of the 
biomaterial, this inflammation typically relies on the action of macrophages and is of 
relatively short (less than one week) duration. If inflammation persists for more than 
approximately 1 week, chronic inflammation, characterized by the presence of monocytes 
in the affected area, may result. Over time, these monocytes may differentiate into 
macrophages and lead to the formation of foreign body giant cells.  [7-9, 122-126].  
In the absence of chronic inflammation, the repair and remodeling phase of 
healing continues and the implant site is stabilized. The implant is incorporated into a 
collagenous fibrous capsule. The nature of this capsule is dictated by both the 
composition and structure of the implant material and by the location of the implant [125, 
127-129]. For non-toxic, non-degradable materials, minimal fibrosis may be observed 
[130-131]. If implants are composed of more reactive materials, the resulting 
encapsulation becomes more extensive and consists primarily of collagen with some 
fibroblasts and macrophages [125, 131]. Materials that elicit a strong foreign body 
response result in the formation of a thick, fibrous capsule formation and may impede 
integration of the implant with native tissue. Finally, if a more pronounced 
incompatibility is seen, a more significant immunological response may be induced. In 
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this instance, rejection of the implant by the immune system or remote effects may occur 
[125].  With these difficulties, it is apparent that conventional implant technology leaves 
much to be desired.    
Recent advances in biomedical research have focused on controlling the body’s 
response to implant materials by careful selection and engineering. If the effect of these 
biomaterials on the body can be controlled, implants with much better function and 
applicability can be imagined.  Numerous attempts to modulate the body’s response have 
been investigated.  For example, the use of materials such as Dacron® and Gore® for use 
in vascular grafts and the use of modern alloys in articular replacements have greatly 
improved the function of these implants and reduced the incidence and severity of 
adverse reactions in the body.  The poor biointegration often seen with these materials 
and their inherent inability to repair damage still represent significant deficits in their 
long-term function [132].  The development of more complex biomaterials remains a 
major area of research and shows great promise to address a number of critical needs in 
the medical field. 
The body’s response to biomaterials is very similar to the previously described 
post surgical adhesion formation process (see Section 2.2). These parallels provide 
insight into the desired properties of materials employed for the prevention of PSA. 
Strategies that have previously been shown to attenuate the foreign body response 
observed with implanted biomaterials are expected to provide excellent opportunities for 
reducing the incidence of PSA. It is thought that, by minimizing the body’s response, 
development of an extended FGM matrix can be controlled in much the same way that 
many successful biomaterials avoid a strong foreign body response.   
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2.5.3. Polyethylene Glycol 
One particular material that is the subject of much current research is 
polyethylene glycol (PEG).  This material, often referred to as polyethylene oxide (PEO) 
in higher molecular weight forms, has been shown to be biocompatible in a number of 
applications and is under investigation for a variety of additional uses.  PEG consists of a 
series of repeating –(CH2CH2O)– units with hydroxyl terminations at both ends.  This 
structure results in PEG’s having an amphiphilic nature that renders it resistant to protein 
adsorption.   
While soluble in many organic solvents, PEG is highly hydrophilic and has been 
shown to form PEGylated surfaces with a hydrated layer with a large excluded volume 
and high steric stabilization [90-91]. Such a surface presents few binding sites for protein 
interactions, and the adsorption of protein and subsequent adhesion of cells is strongly 
inhibited.  Recent studies incorporating low concentrations of PEG into polylactic acid 
have been shown to reduce the level of cellular adhesion dramatically [133].  In addition 
to its resistance to fouling, PEG can also form hydrogels.  In this form, PEG’s 
consistency can be tailored to match the native or surrounding tissue for implant 
applications. 
This unique structure, coupled with its lack of toxicity, has led to PEG’s 
investigation for use in numerous biomaterials applications.  Many controlled drug 
delivery systems exploit PEG to create “stealth” technologies.  Nanoscale materials can 
be injected into the bloodstream; since they are unable to be seen by immune cells, they 
can achieve very long circulation times and extend drug delivery therapy.  Other drug 
delivery systems employ PEG in stationary reservoir systems to avoid fibrous capsule 
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formation [134].  More recently, PEG has been investigated for use in biosensor and 
numerous other biomedical applications [135]. This wide-ranging applicability at 
rendering surfaces resistant to cell and protein adhesion and well-characterized 
biocompatibility suggest that PEG should be an ideal material for use in PSA adhesion 
technologies.  
2.6. Targeting and Controlled Delivery 
Successful medical treatment of many conditions is hampered by numerous 
factors. In order to treat a disease in the body, it is often necessary to deliver a drug to a 
specific area and to maintain therapeutic concentrations for an extended period of time 
[134]. The desire to maintain these concentrations, frequent dosing at high levels can lead 
to systematic complications. For example, many chemotherapies for the treatment of 
cancers require daily dosing and can lead to side effects including nausea, loss of hair, 
and anemia [136-140].  
In order to maximize the efficacy of treatments and to reduce these side effects, it 
would be advantageous to deliver the desired drugs to the affected areas of the body and 
release them at a rate that would maintain the therapeutic concentration in the local area. 
Vigorous research is underway to investigate technologies that will facilitate such 
treatments. Many advanced drug delivery systems have been designed to extend the 
therapeutic treatment window. These systems vary from relatively simple extended 
release tablets to complicated pulsatile delivery systems with feedback loops that respond 
to changes in the physiological environment [134, 141-145].  
Another technique that can be used to minimize side effects while achieving the 
maximum benefit from a treatment relies on delivering the therapy only to the affected 
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area(s) of the body. Simple embodiments of this concept include external application of 
ice to swollen joints, injection of anti-inflammatory drugs, or the application of topical 
antibiotics. The treatment of many disease conditions, however, requires that potentially 
toxic drugs be delivered to specific areas within the body. In order to address this goal, 
drug delivery systems have been developed to deliver agents specifically to affected areas 
of the body.  
For therapeutic agents delivered via the vasculature, this targeted drug delivery 
can occur through two unique mechanisms. Passive targeting often relies on the enhanced 
permeability and retention (EPR) effect to facilitate delivery of drugs to tumor sites [146-
149]. Because of their rapid growth, tumor sites often develop vasculature with large 
pores. This “leaky” vasculature allows nanosized drug carriers to reach these sites, where 
they are able to release therapeutic agents at the pathological sites. Alternatively, active 
targeting relies on specific ligand-target interactions to direct drugs to the desired site in 
the body. Recent developments in chemical and biochemical techniques have led to 
advances in the area of active targeting. By designing drugs or drug carriers to seek out 
these specific sites in the body, the efficacy of therapeutic treatments can be enhanced 
while the potential for adverse side effects can be greatly reduced [146, 150-152]. Major 
advances in this field have demonstrated excellent results in the treatment of numerous 
cancers, diabetes, and vascular disease [153-160]. 
This active targeting can be carried out using a variety of targeting units. 
Antibodies for specific molecules, including fibrin, can be conjugated to nanoparticles or 
liposomes in order to direct targeting [161]. These antibodies, however, are not ideal for 
targeting of small molecules. Because of their very large size (~ 150 kDa), the antibody 
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could mask the effect of polymers delivered to surfaces. In addition, since they are 
biologically derived, they are likely to elicit an undesired response in the body. Aptamers, 
small strands of nucleic acid, can also be employed to provide specific binding to 
molecules [162-163]. These targeting units can be isolated by iterative selection and 
amplification in vitro from a random pool of nucleic acid strands. A similar approach 
using bacteriophages for amplification can be employed to select peptide units for 
targeting [164]. These targeting approaches result in the identification of small, easily 
synthesized molecules that can then be incorporated onto the therapeutic molecule or 
carrier [163, 165-167]. 
These small targeting units provide advantages over antibody targeting. First, 
since the targeting unit is relatively small, multiple groups can be incorporated into the 
structure to amplify the effect of targeting without the likelihood of masking the 
protective properties of the polymers. In addition, since they are not biologically derived, 
they have a low probability of eliciting an immunological response from the body.  
2.6.1. CREKA Targeting Peptide 
A particular targeting technology has recently been developed as a means to target 
drug carriers to tumor cells based on the presence of clotted plasma proteins that 
accumulate due to the leaky vascular associated with rapidly growing tumors [168-170]. 
This new targeting agent, based on the pentapeptide unit Cysteine-Arginine-Glutamic 
Acid-Lysine-Alanine (CREKA), has been shown to enhance delivery of nanoparticles 
and nanoworms to tumor sites. In initial investigations, superparamagnetic iron oxide 
(SPIO) nanoparticles were conjugated with CREKA and successfully targeted to growing 
tumors in mice [171]. If the fibrinogen knockout mice were used in the experiment, no 
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targeting was observed, confirming that the targeting mechanism relies on specific 
interaction of the peptide unit with clotting proteins. Subsequent studies verified the 
ability to target clinically approved chemotherapeutic nanoparticles in mice [172]. The 
effect of  changes in the shape of the targeted nanoparticle and the density of targeting 
peptides has also been carried out [173]. This peptide has also been shown to be effective 
at targeting nanoparticles to atherosclerosis plaques for diagnosis and therapy [174]. 
In order to improve the understanding of CREKA and to develop functional 
analogs, several modeling studies using molecular dynamics have been conducted. Initial 
modeling of the three-dimensional structure of the peptide in aqueous solutions and on 
the surface of nanoparticles indicated that the conformation is unchanged by surface 
attachment via the cysteine residue [175]. Subsequent models indicated the relative 
stability of the three-dimensional structure of the CREKA unit with the addition of dye 
molecules or with substitution of protease-resistant arginine analogs [176-177]. While the 
nature of the interactions of this peptide with fibrin is not well understood, the 
effectiveness of its targeting ability and its robust three-dimensional structure make it an 
attractive ligand for the targeting of materials to fibrin.  
2.7. Conclusion 
Post-surgical adhesions represent a significant clinical complication that affects a 
large patient population. To address this multifaceted problem, a range of methods were 
developed. Although use of physical material barriers provides the best results, no single 
method has proven to be effective in all instances, to date. This failure is most likely due 
to the complexity of PSA formation, the uniqueness of each surgical procedure and 
patient, and lack of understanding of the underlying mechanism of PSA etiology and 
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successful prevention. PSA remains a serious clinical problem. New methodologies to 
improve material/device performance at a mechanistic level are a necessity for the 
success of PSA barriers in the future. In addition, novel materials must be designed and 
formulated to address all pertinent aspects of the PSA formation (e.g., physical, chemical, 
inflammatory, oxidative, and wound healing) in order to maximize the potential for 
clinical success.  In this regard, biomaterial engineers could make crucial contributions 
toward eventual elimination of PSA formation. 
This dissertation describes the design, synthesis, and evaluation of a series of 
polymeric biomaterials for use as prophylactic adhesion barriers. Based on a thorough 
understanding of the underlying biochemistry and pathology of PSA formation, the 
materials were specifically designed to interrupt the cascade of events that leads to 
adhesion formation. Applying tools from polymer chemistry, organic chemistry, and 
analytical chemistry, these materials were synthesized and fully characterized. The 
function of these materials was evaluated in model systems, and the relationship between 
their structure and function was assessed using statistical techniques. Finally, the ability 
of these materials to inhibit PSA formation in vivo was evaluated.  
 
 
 
 
 
 
Copyright © John M. Medley 2010 
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Figure 2-1 An example of intestinal post-surgical adhesion (PSA) formation.  
In a rat model, sections of mecum and ileum were abraded using dry gauze 
until hemorrhage formed. Fourteen days post surgery, adhesion formation 
was visualized. Figure reproduced with permission from Kutlay, et al. 
[178]. 
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Figure 2-2  Stages and time course of the wound healing process.  
Initially, a high concentration of fibrin is observed in the peritoneal fluid. 
Polymorphoneutrophils PMNs are observed within approximately two 
days post tissue-trauma, followed by macrophages. Reperitonealization 
occurs with the appearance of mesothelial cells within the first five days, 
and vascularization begins within 1 week following tissue damage. 
Adapted from [126]. 
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Table 2-1 Timeline of events occurring during post-surgical adhesion formation. 
 
1. Damage to the peritoneal mesothelium exposes an acellular, denuded 
surface, known as the “basement membrane”, which consists primarily of 
type I collagen, type II collagen, fibronectin, and laminin [6, 8]. 
2. As the vasculature constricts, homeostasis is obtained and the coagulation 
cascade begins with the deposition of fibrin [8].  
3. The quantities of fluid and plasma proteins increase near the site of injury 
and an inflammatory exudate develops within the peritoneal fluid [7].  
4. The composition of this exudate, initially consisting primarily of 
neutrophils, changes. If there is no infection, it becomes rich in 
macrophages over the course of 24 hours [7-8]. 
5. Epithelial cells are deposited on the surface of the injury by a process 
called “island implantation” and re-epithelialization of the peritoneal 
surface proceeds [7].   
6. The fibrin gel matrix (FGM), considered the “principal player in adhesion 
formation,” consists of fibrin, fibronectin, hyaluronic acid, 
glucosaminoglycans and proteoglycans, and forms 72-108 hours after 
surgery [7-8]. 
7. The FGM is remodeled and strengthened, for approximately 1 month [8-
9]. 
8. The FGM is slowly replaced by fibrous collagen molecules and 
vascularized in a process controlled, at least partially, by macrophages [8].   
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Table 2-2  Structure of Materials Used for Adhesion Prevention 
 
Hyaluronic Acid (HA) 
 
Carboxymethylcellulose 
(CMC) 
 
Phospholipid 
 
“Adept” Icodextrin 
 
Polyethylene Glycol 
(PEG) 
 
Poly (L-Lysine) 
 
Poly (L-Glutamate) 
 
Polyethylene (PE) 
 
Poly 
(Tetrafluoroethylene) 
(PTFE)  
Cellulose 
 
“SprayGel” System 
 
  
Table 2-3  Summary of Techniques used to Prevent Post Surgical Adhesions 
 
 Technology 
Application 
Method 
Biodegradability Level of Tunable Properties Level of Success References 
M
od
if
ic
at
io
n 
of
 
Su
rg
ic
al
 T
ec
hn
iq
ue
 Non- Suturing of Damaged 
Peritoneum 
N/A N/A N/A 
Significant decrease in PSA formation, but adoption of this practice by 
surgeons problematic 
[1-2, 13, 24-26] 
Use of Laparoscopic 
Procedures 
N/A N/A N/A 
Significant decrease in PSA formation, but: 
• Application of technique is limited to certain surgeries 
• Precludes use of many other adhesion-reduction techniques 
[34-36] 
Other Technique Changes  
(Non-powdered gloves,  non-
use of drainage tubes, increased 
tissue oxygenation) 
N/A N/A N/A 
Significant decrease in PSA formation, but adoption of this practice by 
surgeons is problematic [1-2, 31, 33] 
P
ha
rm
ac
eu
ti
ca
l 
In
te
rv
en
ti
on
s 
Anti-Inflammatories IP injection Yes 
Dose, timing, and selection of 
the therapeutic agent 
Moderate success because of the associated risk of side effects [37-38] 
Antioxidants IP injection Yes Dose can be altered 
Very successful.   
• Vitamin E interrupts several parts of the adhesion formation 
mechanism. 
[45-46] 
Fibrinolytic Agents IP Injection Yes Dose can be altered 
Moderately successful but has potential for immunogenic response and 
reduced hemostasis [9, 49-50, 52-54] 
Chymase Inhibitors Oral Delivery Yes 
Dose and timing of the 
therapeutic agent can be 
altered 
Moderately successful [59] 
P
er
it
on
ea
l I
ns
ti
lla
te
s 
Hyaluronic Acid and its 
Derivatives 
IP injection Yes MW and dose of HA can be 
optimized 
Moderately successful [64-71, 76-77] 
Phospholipids IP injection Yes Dose can be optimized 
Very effective. 
• The zwitterionic nature of the phospholipids allows them to bind onto 
the epithelial cell membranes and provide lubrication 
[79-82] 
Hydroflotation Initiators 
(“Adept”) 
IP Injection Yes 
MW and dose of the starch 
molecules can be optimized 
Moderately successful [83-89] 
Poly(ethylene glycol) IP injection Yes 
MW and concentration of 
PEG solution can be 
optimized 
Moderately successful: 
• Significant decrease in number and collagen content of PSAs 
[4, 90-91] 
A
dh
es
io
n 
B
ar
ri
er
s 
Polytetrafluoroethylene  
(“Gortex Surgical 
Membrane”, “Preclude”) 
Film placed 
directly on the 
damaged tissue 
No Physical properties of the 
mesh can be controlled 
Moderately successful: 
• Non-degradable; it remains in site and must be removed with another 
surgical procedure 
• Requires suture fixation 
• Incompatible with laparoscopy 
[95, 99-102] 
Oxidized Regenerated 
Cellulose (“Interceed”) 
Film placed 
directly on the 
damaged tissue 
Yes 
MW, degree of oxidation, and 
the physical properties of the 
film can be controlled 
Moderately successful: 
• Thrombogenic 
• Difficult to handle 
• Incompatible with laparoscopy 
[48, 102, 107] 
Cross-Linked Hyaluronic 
Acid Gel (“Seprafilm”) 
Film placed 
directly on the 
damaged tissue 
Yes MW and degree of the cross-
linking can be optimized 
Very successful: 
• Adheres to the peritoneum 
• Degrades 
• Is not procoagulant 
But causes: 
• Severe inflammation 
• Abscess formation 
• Must be placed directly on the damaged tissue 
[102-104] 
in vivo Polymerization of 
Poly(ethylene glycol)  (“Spray 
Gel”) 
In vivo spray 
polymerization Yes 
MW and degree of 
polymerization can be 
optimized 
Very effective; can be employed with laparoscopic procedures [105-106, 110] 
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Table 2-4  Animal Models used to Evaluate Post Surgical Adhesion Prevention 
Strategies 
 
  
Tissue(s) 
Involved 
Animal 
Model Pros Cons References 
Abdominal 
Wall 
Mouse 
Measure both extent and 
type of adhesion 
Semiquantitative scoring [33] 
Rat 
Quantitative analysis of 
adhesion area 
 [93-94] 
Rabbit 
Surgical damage 
carefully controlled 
Semiquantitative scoring [80-81] 
Intestinal wall Rat  Semiquantitative scoring [111-112] 
Intestine / 
Abdominal  
Wall  
Rabbit 
Surgical damage 
carefully controlled 
 [82] 
Rabbit  Semiquantitative scoring 
[38, 69, 
113, 179] 
Uterus  
Hamster  Semiquantitative scoring [59] 
Pig 
Internal control possible 
by treating two uterine 
horns separately 
 
Semiquantitative scoring [105] 
Rabbit Internal control possible Semiquantitative scoring [31, 97] 
Rat 
Internal control possible 
Quantitative area result 
 
[46, 89, 
100] 
Uterus 
Reformation 
Mouse Multiple Adhesion  Semiquantitative scoring [64] 
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Table 2-5  Scoring Methodology Employed to Evaluate Post Surgical Adhesion 
Prevention Strategies 
 
 
 
 
 
 
 
 
 
 
 
 
 
Score Extent of Adhesion Severity Degree 
0 None No adhesions No adhesions 
1 1-25% Filmy, avascular  
Adherent tissue separate 
with gentle traction 
2 26-50% Vascular and/or opaque 
Tissue layer separation 
requires moderate traction 
3 51-75% Cohesive attachment 
Tissue layer separation 
requires sharp dissection 
4 76-100%   
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CHAPTER 3. RESEARCH GOALS 
 
3.1. Introduction 
In this project, we have developed a series of targeted polymeric biomaterials and 
investigated their utility as a prophylactic treatment for the prevention of post surgical 
adhesions. In order to address this real-world problem, the integration of knowledge from 
numerous fields is required. The molecular design of the final polymer is based on the 
biological and biochemical environments of interest and the desired mechanical and 
biomaterial properties. Knowledge of organic chemistry and analytical chemistry 
facilitates the synthesis and characterization of these materials, and the framework of 
chemical engineering integrates these varied fields and provides the basis for functional 
evaluation and enhanced understanding.  
By applying a fundamental understanding of the biochemistry, physiology, and 
pathology of adhesion formation, the materials were specifically designed to meet this 
clinical need. Using well controlled polymerization chemistry and subsequent 
functionalization, several structural properties were varied and the affect of this structure 
was evaluated in numerous in vitro models. Finally, the results of these investigations 
were employed to select a combination of materials to be evaluated in vivo in a rabbit 
model. This methodical, ground up approach, provides unique insight into the 
relationship between the molecular structure of these materials and their performance as 
adhesion barriers and increases the likelihood for the development of a viable method to 
address this clinical need. This approach to biomaterial development and its initial success 
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should lead to significant additional research into the use of self-assembled systems for PSA 
prevention and in other applications, including tissue adhesives and oral barriers. 
3.2. Objectives and Significance 
The following general hypothesis was proposed to direct this research: 
 
Polymeric materials can be designed to assemble in situ by targeting biomarkers 
of tissue damage and provide protection from the formation of post surgical 
adhesions. 
 
In order to investigate this hypothesis, the project was conducted in three distinct 
stages, described below as specific aims, each of which was carried out to test a specific 
hypothesis. 
3.2.1. Specific Aim 1: Design, synthesis, and characterization of polymers to be 
used for the in situ formation of adhesion barrier. 
In order to develop a new material for use as a prophylactic treatment to prevent 
PSA formation, three stages of synthesis and characterization were addressed: 
 
1. Synthesis of block copolymers incorporating poly(methacrylic acid), 
reactive methacrylate monomers, and poly(ethylene glycol) functionality 
with highly-controlled molecular weight and polydispersity.  
2. Functionalization of polymers for the addition of cross-linkers and fibrin-
specific peptides. 
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3. Implementation of polymer characterization methods using available tools, 
including proton nuclear magnetic resonance spectroscopy (1H-NMR), gel 
permeation chromatography (GPC), and high performance liquid 
chromatography (HPLC). 
3.2.1.1. Hypothesis #1  
Group transfer polymerization can synthesize a variety of methacrylic acid 
based polymers with multiple functionalities and precisely controlled 
molecular architecture for in vitro evaluation. 
3.2.1.2. Significance and Outcomes 
Efforts to test this hypothesis are described in Chapter 4. As described in this 
section, we have fully implemented the methodology to perform group transfer 
polymerization (GTP) in our laboratory. The ability to polymerize various monomers has 
been established, as has a selective deprotection strategy, allowing multiple 
functionalities to be added sequentially. Methods to characterize these materials using 
1H-NMR, GPC, and HPLC have been realized. We have synthesized diblock copolymers 
containing functionalized methacrylic acid units with targeting moieties and pendant 
polyethylene glycol chains. These polymers exhibit precise control of both the molecular 
weight and polydispersity of individual polymer blocks.  
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3.2.2. Specific Aim 2: Investigation of non-targeted statistical and block 
copolymers interactions with model surfaces.  
The second phase of this research focused on the evaluation of non-targeted 
polymeric biomaterials using a variety of in vitro test methods. This stage can be divided 
into three sub-stages: 
 
1. Investigation of the kinetics, thermodynamics, and conformation of non-
targeted polymer adsorption to model surfaces. 
2. Evaluation of polymeric biomaterials to block non-specific protein 
adsorption. 
3. Reduction of cellular attachment by non-targeted block and statistical 
copolymers on positively charged self-assembled monolayer surfaces. 
3.2.2.1. Hypothesis #2 
Non-targeted block copolymers with high charge density will interact more 
readily with charged model substrates as compared to statistical copolymers. The 
kinetics and thermodynamics of these interactions and the structure of the 
resulting surface layer can be characterized by quartz crystal microgravimetry 
and cellular attachment assays.  
3.2.2.2. Significance and Outcomes 
The quartz crystal microbalance was proven to be an effective, efficient method to 
probe the interaction of the polymers of interest with positively charged model surfaces. 
By fitting a simple adsorption model to the observed adsorption phenomena, it was 
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possible to quantify the kinetics and equilibrium surface coverage of these materials. This 
work, described in Chapter 5, supported the hypothesis that non-specific protein 
adsorption can be modulated by varying the structure of the polymer. Finally, depending 
on the particular molecular architecture employed, these materials also proved effective 
at reducing the level of cellular attachment to surfaces.  
3.2.3. Specific Aim #3: In vitro evaluation of targeted copolymers to reduce events 
leading to fibrin gel propagation and assessment of targeting specificity.  
The final aspect of this research project focused on the investigation of targeting 
in order to enhance the ability of block copolymers to function as desired. This work was 
carried out in two phases: 
 
1. Investigation of targeted block copolymers to modulate aspects of fibrin 
gel matrix propagation, including fibrinogen adsorption, fibrin gel 
propagation, and cellular attachment. 
2. Evaluation of interactions of targeting peptides and targeted polymers with 
fibrin and fibrinogen.  
3.2.3.1. Hypothesis #3 
Using targeting peptides, block copolymers can be tailored to bind effectively to 
markers of damaged tissue. Binding to fibrin, these PEG containing polymers 
will render the growing fibrin gel matrix less susceptible to subsequent 
fibrinogen deposition and cellular attachment, thereby attenuating propagation 
of the FGM. 
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3.2.3.2. Significance and Outcomes 
The investigation of hypothesis #3 represents the culmination of the work carried 
out in the previous investigations. As described in Chapter 6, the incorporation of 
targeting peptides and the careful control of molecular architecture can be used to 
moderate the propagation of the fibrin gel matrix. The polymers interact strongly with 
fibrin surfaces and reduce the rate and degree of subsequent fibrinogen deposition. In 
addition, they provide protection against cellular attachment on model fibrin surfaces. 
 The investigations described in Chapter 7 confirm the ability of these targeted 
materials to interact with fibrin(ogen). Although the effect was less pronounced than 
anticipated, the molecular architecture of the polymer affects the structure of the fibrin 
fibrils in the growing fibrin gel matrix. Finally, the targeting peptides, as well as the 
scramble peptide used as a control, both interact strongly with solution phase fibrinogen 
and result in a large conformational change in the protein.  
 
 
 
 
 
 
 
 
Copyright © John M. Medley 2010 
 42 
 
 
CHAPTER 4. POLYMER SYNTHESIS AND CHARACTERIZATION 
 
 
4.1. Introduction 
In order to test the hypothesis that polymeric materials can be employed to 
assemble in situ and provide protection from the formation of post surgical adhesions, we 
first set out to design the appropriate materials to test. By designing this material from the 
ground up, we were able to select and tune the biocompatibility of the materials, include 
desired functionality, and tailor the architecture of the molecules. Employing group 
transfer polymerization allowed the synthesis of block copolymers containing various 
functionalities and provided precise control over the molecular weight of the various 
blocks.  To minimize the potential for adverse biological interactions, the selection of 
materials was limited to those that have previously been shown to exhibit 
biocompatibility. Specifically, non-toxic and non-immunogenic materials were required.  
In addition, the potential to incorporate multiple functional groups and to control the 
molecular weight of the polymerization were desired. Finally, materials were selected 
that were expected to provide excellent barrier properties and prevent the adsorption of 
proteins.  
Methacrylic acid was selected as the monomer for the polymer backbone for 
several reasons. First, methacrylate polymers have been employed and have shown 
excellent biocompatibility in many applications [180-183]. While some studies have 
employed polyacrylic acid as an adjuvant to heighten the body’s immune response to 
vaccination formulations, the nature of this reaction is believed to stem from the high 
molecular weight and the large concentration of acidic units employed [184-185]. While 
 43 
 
 
we anticipate that these effects can be modulated by controlling the polymer architecture, 
they will be investigated in future studies. Finally, methacrylic acid can be readily 
functionalized with a variety of functional groups, many of which are commercially 
available or can easily be prepared in the laboratory.   
In order to provide resistance to the adsorption of proteins and interrupt 
subsequent adhesion formation, polyethylene glycol (PEG) was chosen. This polymer has 
been used in a variety of biomaterials applications in order to provide protection from 
protein adsorption and from immunological response in vivo [118, 134]. Because of its 
highly hydrophilic nature, water associates strongly with PEG in aqueous environments 
and the polymer typically exists in a gel state.  This structure resembles the extracellular 
matrix and provides high steric protection in the body [90-91]. Numerous examples can 
be found employing PEG to create “stealth” drug delivery systems with long circulation 
times [134, 186-188]. To incorporate PEG into our polymer system, commercially 
available methoxy polyethylene glycol methacrylate with a PEG chain length of 
approximately 25 PEG repeat units (MPEGMA1100, Aldrich) was selected for use. 
The target molecular weight for polymer synthesis was chosen to meet a variety 
of requirements. First, it has previously been demonstrated that the maximum reduction 
in protein adsorption is observed with PEG chains with a molecular weight of 5,000 
g/mol [189]. The maximum molecular weight of the polymer was set at 50,000 g/mol to 
ensure rapid renal clearance of any material entering the bloodstream [134]. The initial 
polymer synthesized for use in this investigation incorporated a block of t-butyl 
methacrylate (TBMA) and a block of MPEGMA1100; the target molecular weights of 
these units were each set at 5,000 g/mol. 
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In order to assess the relationship between polymer structure and function, and to 
ensure repeatability between synthetic batches, it was necessary to employ a highly 
controlled polymer synthesis. Group Transfer Polymerization (GTP), shown 
schematically in Figure 4-1, was utilized to synthesize the backbone polymers used in 
these studies. This technique allows the synthesis of polymers with controlled molecular 
weight and polydispersity. In addition, statistical and block copolymers can readily be 
created by reacting multiple monomer units with either simultaneous or sequential 
monomer addition. 
4.2. Materials and Methods 
4.2.1. Synthesis and Characterization of Protected Backbone Polymers  
Using modifications of previously published reaction schemes, the synthesis was 
carried out as shown in Figure 4-2 [190-194]. Solvent was prepared by drying 450 ml 
THF (Mallinckrodt) over a mixture of sodium (4 g, Aldrich) and benzophenone (8 g, 
Aldrich) until the purple color characteristic of the dianion was observed. The proton 
scavenger bis(dimethylamino) methylsilane (ABCR, Gelest) was distilled under vacuum 
and stored in a freezer under argon prior to use. TBMA (Aldrich) and (MN = 300, 
MPEGMA300, Aldrich), was passed through an inhibitor removal column, distilled, mixed 
with ABCR (2 wt%), and stored in a freezer under argon prior to use. MPEGMA1100 was 
dissolved in inhibitor free THF (Aldrich), passed through an inhibitor removal column, 
and dried under vacuum overnight. This macromer was dissolved in dry, air-free THF to 
a concentration of 0.4 g/mL, mixed with 2% ABCR, and stored under argon in freezer 
prior to use. 1-methoxy-1-(trimethylsiloxy)-2-methyl-1-propene (MTS, Gelest), was 
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vacuum distilled and stored under argon in freezer prior to use. The catalyst, 
tetrabutyyammonium bibenzoate (TBABB) was prepared as has previously been 
described and stored under nitrogen prior to use [195]. Prior to polymerization, all 
glassware was dried overnight at 180 oC, assembled hot, and flamed under vacuum to 
remove residual water.  
Approximately 10 mg TBABB was added to the reaction flask under inert 
atmosphere. Approximately 15 mL of dry, air free THF was added to the flask by solvent 
transfer. The initiator, (MTS, 93.3 mg, 0.53 mmol) was added via syringe under argon 
and allowed to stir for 15 minutes at room temperature. To form a block copolymer, 1.97 
g TBMA (13.9 mmol) was added to the reaction vessel via syringe under argon. No 
apparent exotherm was observed. The reaction was allowed to proceed under argon for 
30 minutes, at which time approximately 5 mL was removed for analysis and quenched 
with methanol. A solution of the second monomer, MPEGMA1100, (5 mL, 1.8 mmol) was 
then added to the reaction vessel and allowed to react for 90 minutes. The reaction was 
quenched with methanol, the solvent was removed with vacuum, and the product was 
dried for 48 hours under vacuum. Based on the stoichiometry, the molecular weights for 
the TBMA block and the MPEGMA1100 block were predicted as 3,700 and 5,900 g/mol, 
respectively, and the ratio of TBMA blocks to MPEGMA1100 was predicted to be 5.1:1.  
Block copolymers of MPEGMA300 and TMBA were prepared similarly. 
Additionally, statistical copolymers were synthesized using the same technique, with 
simultaneous addition of the two monomers. Finally, a homopolymer of TBMA was 
prepared using the same technique. The resulting polymers were dissolved in deionized 
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water and purified by triplicate ultrafiltrations with Ultracel Amicon YM membranes 
with appropriate molecular weight cutoffs and isolated by lypholization. 
4.2.2. Deprotection of tert-Butylmethacrylic Acid Group 
A modification of a previously described procedure was used to convert the 
TBMA groups to methacrylic acid groups [194]. As shown in Figure 4-2, hydrolysis was 
carried out by refluxing in 1,4-dioxane (Aldrich) with p-toluenesulfonic acid (PTSA, 
Aldrich) for 20 – 96 hours. The resulting polymers were purified by triplicate 
ultrafiltration and isolated by lypholization.  
The polymers were characterized by gel permeation chromatography (GPC) and 
by proton nuclear magnetic resonance spectroscopy (1H-NMR). GPC was carried out 
using a Shimadzu Prominence High Performance Liquid Chromatography system 
equipped with a Waters Refractive Index Detector (RID). All analyses were conducted in 
THF using Waters HR1 and HR2 columns in series with an Agilent PLGel Mixed B 
column, a flow rate of 1.0 mL/min, and referenced to narrow molecular weight 
polystyrene standards (Polymer Laboratories). The molecular weight distribution of the 
polymers was determined using the Shimadzu LabSolutions software.  
Proton NMR analysis was conducted by dissolving the polymer in deuterated 
chloroform (Cambridge Isotopes) and measuring the resonance with a Varian Gemini 200 
MHz NMR spectrometer. Mestralab Research’s MNova software was employed to 
analyze the NMR spectra. 
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4.2.3. Polymer Conjugation with N-Aminoethylmaleimide Crosslinker 
Peptide functionalization of polymers was achieved through sulfhydryl directed 
maleimide chemistry. Maleimide was introduced into the structure of the fully 
deprotected polymers by the coupling of N-aminoethylmaleimide trifluoroacetic acid 
(NAEM, Aldrich) [196-197]. This moiety was covalently attached to the polymer via a 
stable amide linkage, leaving the maleimide group available for subsequent peptide 
conjugation. 
As shown in Figure 4-3, the primary amine group of the crosslinker was 
conjugated to the free acid groups in the polymer chain to form amide bonds using well 
known diimide chemistry [198-199]. Two equivalents of NAEM, based on the number of 
free acid groups present, were combined with the polymer (1 equivalent of acid groups) 
and 1.1 equivalent of N,N’-dicyclohexylcarbodiimide (DCC, Aldrich) and dissolved in 
acetonitrile (ACN, Fisher). This reaction mixture was stirred at room temperature in the 
dark for 2 hours. Successful conjugation was indicated by the precipitation of insoluble 
N,N’-dicyclohexylurea (DCU) precipitate that began to form after approximately 5 
minutes of reaction. After reacting for 2 hours, the excess DCC was quenched by adding 
excess acetic acid (HAc, Fisher) and stirring for 10 minutes. The DCU was then removed 
by centrifugation, leaving a clear yellow solution. 
Excess NAEM was removed from the reaction mixture by repeated aqueous 
extraction from diethyl ether. Upon dissolution in ether, the reaction mixture formed a 
cloudy liquid, indicating the insolubility of NAEM in the solvent.  The clear ether layer 
that remained after extraction was evaporated. The white solid product was dissolved in 
acetone, and the solvent was removed by evaporation. HPLC analysis was conducted on 
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the Shimadzu Prominence HPLC system to confirm the purity of this product. This 
analysis was carried out with a Restek Viva C18 5 µm 4.6 x 150 mm HPLC column at a 
controlled temperature of 40 oC with an isocratic mobile phase consisting of 90% DI 
water with 0.1% trifluoroacetic acid (TFA, Aldrich) and 10% methanol (Fisher). This 
material was stored at -20 oC for subsequent peptide conjugation. 
4.2.4. Conjugation of Peptides to Polymer 
Two five unit oligopeptides were incorporated in the crosslinker-conjugated 
polymers via the specific reaction between the sulfhydryl group on cysteine and the 
maleimide group on the crosslinker. Both peptide chains included the amino acids alanine 
(A), arginine (R), cysteine (C), glutamic acid (E), and lysine (K). The first peptide 
employed, CREKA, was employed to target the polymers to fibrin, while the second 
peptide, CAERK, was used as a control. Both of these materials were produced 
specifically for this study by Celtek Biosciences. 
The peptide conjugation reaction was carried out at room temperature in a 
solution containing 50% ACN and 50% PBS as shown in Figure 4-4. The NAEM-
conjugated polymer was dissolved in this solution, and the desired amount of peptide (3-9 
peptides per polymer chain) was added to the solution. This reaction mixture was stirred 
at room temperature in the dark for five hours. Excess cysteine was added to consume 
unreacted maleimide groups, and the reaction was allowed to proceed for one hour. After 
removing the solvent in vacuo, approximately 3 mL of acetone was added. Insoluble salts 
were removed by centrifugation, and the product was isolated by evaporating the solvent 
with a stream of dry nitrogen.  
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4.2.5. Purification of Polymer-Peptide Conjugates 
HPLC analysis was conducted to assess the purity of the reaction mixtures. As 
shown in Figure 4-5, the reaction mixture contained several products. In order to achieve 
a pure product for analysis, preparative HPLC was employed to isolate the desired 
peptide conjugate from the reaction mixture. The Shimadzu Prominence HPLC system 
was used, with a Shimadzu Viva C18 21.2 x 150 mm column. The isocratic mobile phase 
consisted of 90% DI water with 0.1% trifluoroacetic acid (TFA, Aldrich) and 10% 
methanol (Fisher). The polymer conjugate, which eluted around 7 – 10 minutes, was 
isolated by collecting appropriate fractions, and the solvent was removed in vacuo. The 
purity and identity of the products was confirmed by subsequent HPLC and 1H-NMR 
analysis.    
4.3. Results and Discussion 
4.3.1. Polymer Synthesis and Characterization 
In order to synthesize the backbone polymers for this study with the desired level 
of control over the molecular architecture, it was necessary to employ group transfer 
polymerization. Attempts to use anionic polymerization proved to be ineffective due to 
the low temperature required. Although the TBMA monomer is readily soluble in THF at 
-78 oC, the MPEGMA monomer was insoluble at this temperature. Group transfer 
polymerization (GTP) overcomes this limitation, as it can be conducted at ambient 
temperature.  While it allows the desired control over the molecular architecture, the use 
of GTP introduces additional complications into the synthetic scheme. Because GTP is 
highly susceptible to proton quenching, it is necessary to employ aprotic monomers and 
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anhydrous reaction conditions. Since it was desired to synthesize polymers with acidic 
functional groups, synthesis of the polymer backbone was carried out with protected 
monomers using standard Schlenk techniques to maintain inert reaction conditions. The 
desired functionality was then introduced into the polymer by deprotection and 
subsequent conjugation reactions. 
A representative the gel permeation chromatogram of the protected polymer is 
shown in Figure 4-6. As shown in Table 4-1 and Table 4-2, the polymers were 
synthesized with low polydispersity and had molecular weights that were in close 
agreement with the molecular weights predicted from stoichiometry.  Each polymer was 
analyzed by 1H-NMR in deuterated chloroform to confirm the structure and determine the 
relative number of PEGMA units to TBMA units. The resulting NMR, shown in Figure 
4-7, confirms the successful synthesis and purification of the desired polymer. The large 
peak at •  = 3.61 ppm corresponds to the ethyl ether peaks of the PEG chain, while the 
peak at •  = 3.36 ppm represents the three protons on the methyl ether terminus of the 
PEG chain. The peak at •  = 1.40 ppm arises from the t-butyl ether group on the TMBA 
unit, while the broad peaks at •  •  1.1 ppm and •  •  1.8 ppm result from the methyl and 
methylene groups in the polymer backbone. The absence of peaks in the range from 5.5 – 
6.5 ppm indicates that no unreacted monomer remains after purification. By comparing 
the areas of t-butyl ether peak to the area of the methoxy peak, it is possible to determine 
the ratio of TBMA groups to PEGMA groups in the polymer. Combining this result with 
the molecular weight data obtained from the GPC, the number of TBMA and PEGMA 
monomers in each polymer was determined. These results, also summarized in Table 4-1 
and Table 4-2, agree well with the predictions based on stoichiometry. 
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Since the deprotection of the TBMA group results in the formation of methacrylic 
acid groups along the polymer chain, GPC of this product using the previously described 
method was not practical. Instead, the degree of TBMA deprotection in the polymer was 
determined by monitoring the ratio of TBMA to PEGMA using 1H-NMR analysis. 
Figure 4-7 shows the resulting spectrum for this deprotection. The decrease in this ratio 
indicates 80% deprotection of the polymer in this instance. The increase in hydrophilicity 
of the polymer is also indicated by the presence of residual water at •  = 1.5 ppm. As the 
hydrolysis reaction proceeded from 20 to 96 hours, the extent of hydrolysis increased 
from 20% to 100%. Analysis of the reaction mixture confirmed that no cleavage of the 
PEG ester bond occurred during deprotection. Using these results, along with the 
previously determined molecular weight of the protected polymer, the molecular weight 
of the deprotected polymer was calculated.   
4.3.2. Polymer Conjugation with N-Aminoethylmaleimide Crosslinker 
The success of the NAEM conjugation and purification procedure was confirmed 
by 1H-NMR and by HPLC. As shown in Figure 4-8, HPLC analysis confirmed that this 
purification procedure results in a pure polymer conjugate. The combination of the 
unconjugated polymer (r.t. = 5.0 min) and the NAEM (r.t. = 2.4 min) resulted in the 
formation of a new peak (r.t. = 7.7 min). Aqueous extraction from ether resulted in 
quantitative separation of the excess NAEM (water layer) from the product (ether layer). 
NMR analysis confirmed the incorporation of the crosslinker into the polymer structure.  
As shown in Figure 4-9, the PEG peak (•  = 3.57 ppm) and the polymer backbone peaks 
(•  •  1.2) remain intact. In addition, the • -amide is indicated by the peaks at •  = 1.71 and 
•  = 3.75, and the integrity of the reactive maleimide bond (•  = 6.75 ppm) is confirmed.   
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4.3.3. Conjugation of Peptides to Polymer 
The peptide-polymer conjugates were successfully purified using preparatory 
HPLC, as confirmed by analytical HPLC and 1H-NMR analysis. HPLC analysis of the 
reaction mixture, shown in , the reaction mixture contained numerous products. By 
collecting the fraction of the preparative HPLC eluent from 7 – 10 min, the purified 
product was isolated and showed a single analytical HPLC peak (r.t. = 3.9 min). Proton 
NMR analysis of this product confirmed the successful incorporation of the peptide into 
the structure. As shown in Figure 4-9, the disappearance of the maleimide peak (•  = 6.75 
ppm) confirms the complete reaction of the crosslinker. Multiple NMR peaks (•  = 1.20 – 
1.5 ppm and 2.9 ppm) indicates the presence of the peptide in the polymer structure.  
Quantitative analysis of the peptide incorporation into the structure was frustrated 
by the complex NMR spectrum and by the difficulty in making unambiguous peak 
assignment. Fortunately, by monitoring the progress of the peptide conjugation with 
HPLC, it is possible to confirm that the peptide is quantitatively incorporated into the 
polymer structure. Figure 4-10 shows HPLC chromatograms for the starting materials 
(CREKA and P1-N) employed for this reaction. As seen in the two chromatograms 
collected from the reaction at later time points, it is evident that the starting materials are 
both consumed, and that there is only one product peak. As a result of this rapid, 
quantitative reaction between the sulfhydryl group on the peptide and the maleimide 
group on the polymer, it is possible to determine the composition of the resulting polymer 
based on the stoichiometry of the reactants. The materials employed in the untargeted 
analysis and targeting studies are summarized in Table 4-1 and Table 4-2, respectively 
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4.4. Conclusion 
The ability to synthesize and characterize functionalized diblock and statistical 
copolymers for investigation as post-surgical prevention barriers has successfully been 
demonstrated. The robust synthetic methodology that has been developed allows the 
rapid synthesis of block and statistical copolymers of methacrylic acid and PEGMA. 
These materials can be functionalized with targeting peptides. In order to ensure that 
subsequent tests to ascertain the impact of changes in the molecular structure on material 
performance, it is important to note that these materials can readily be isolated as pure 
materials by preparatory HPLC. Using these techniques, we have prepared several 
materials and initial analysis confirms the strong dependence of function on molecular 
architecture. These techniques provide readily accessible methods that are capable of 
avoiding many of the technical challenges that plague functional polymer synthesis. 
 
 
 
 
 
 
 
 
 
Copyright © John M. Medley 2010 
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Figure 4-1 Concerted mechanism for group transfer polymerization.  
The initiator, 1-methoxy-1-(trimethylsiloxy)-2-methyl-1-propene  (MTS) 
reacts with the protected methacrylic acid group. The trimethylsilyl (TMS) 
group is transferred from the initiator to the end of the polymer chain. This 
“living” end propagates the polymerization until the reaction is terminated 
[200]. 
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Figure 4-2 Reaction scheme for the synthesis of poly PEGMA1100-block-(TBMA-co-
MA) by group transfer polymerization.  
In the presence of the initiator (MTS) and catalyst (tert-butylammonium 
bibenzoate, TBABB), tert-butyl methacrylate (TBMA) monomer 
polymerizes via group transfer polymerization. Subsequent addition of 
poly(ethylene glycol) methacrylic acid (PEGMA) facilitates block 
copolymer formation. The MA units are then deprotected by hydrolysis of 
the t-butyl group in refluxing 1,4-dioxane with p-toluenesulfonic acid 
(PTSA).  
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Figure 4-3  Reaction scheme for the conjugation of N-aminoethylmaleimide (NAEM) 
to deprotected polymer.  
Functionalization of copolymer with the crosslinker (NAEM) is conducted 
in the presence of dicyclohexylcarbodiimide (DCC) in acetonitrile (ACN). 
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Figure 4-4  Reaction scheme for the conjugation of peptide to NAEM functionalized 
polymer. 
When the crosslinker functionalized polymer is mixed with peptide, the 
sulfhydryl group on the peptide unit reacts specifically with the maleimide 
group on the crosslinker in a 50/50 mixture ANC and PBS at pH = 7.4. 
Unreacted NAEM groups are then quenched by reaction with cysteine 
groups to prevent subsequent reaction. 
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Figure 4-5  HPLC analysis and purification of peptide conjugate. 
 The HPLC chromatogram for the unpurified reaction mixture (top) 
indicates a mixture of products and unreacted starting materials. 
Preparatory HPLC (bottom) was conducted to isolate the desired product 
(r.t. = 7 – 10 min.). The purified material (middle) shown a single peak for 
the desired product (r.t. = 3.9 min). The peak at 2.7 min. corresponds to 
acetone, used as the injection solvent in this analysis. 
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Figure 4-6 Sample GPC chromatogram for P2-Pro.  
 GPC was conducted and described and referenced to narrow molecular 
weight distribution polystyrene standards. Triplicate analyses of this 
material indicate that MN = 3,120 ± 150 g/mol (M ± SD), MW = 5,020 ± 
280 g/mol, PD = 1.61 ± 0.04. 
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Figure 4-7  1H-NMR analysis of polymeric product. 
Prior to hydrolysis (top), TBMA:PEGMA1100= 3.1  based on peaks at δ = 
1.4 (t-butyl group) and δ = 3.35 (methyl ether), respectively. Hydrolysis 
was determined by evaluating the change in peak ratio. The relative 
change in TBMA intensity (bottom) indicates 80% hydrolysis was 
achieved. The peak at δ = 1.55 indicates residual water bound to the 
hydrophilic polymer. 
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Figure 4-8  N-Aminoethyl Polymer Conjugate Purification. 
 Conjugation of polymer (r.t. = 5.0 min.) with an excess amount of NAEM 
(r.t. = 2.4 min) yields a new peak in the chromatogram (r.t. = 7.7 min). 
Multiple ether/water extractions of the excess NAEM from this reaction 
mixture results in pure NAEM conjugate in the ether layer.  
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Figure 4-9 1H-NMR analysis of unconjugated polymer, NAEM conjugate, and 
peptide product. 
 The unconjugated polymer (P1) indicates the presence of methyl and 
methylene and groups from the methacrylic acid units (broad peak at •  = 
1.2 ppm). In addition, the ethylene glycol and terminal methoxy peaks are 
clearly evident at •  = 3.5 ppm and •  = 3.4 ppm, respectively. Upon 
conjugation with NAEM, the peaks from the aminoethyl group (•  = 1.7 
ppm) and the maleimide group (•  = 6.75 ppm) appear. Upon addition of 
the peptide (CREKA) and cysteine, several peaks corresponding to the 
pentapeptide (•  = 1.0 – 1.5 ppm, •  = 2.9 ppm) are evident. In addition, the 
disappearance of the maleimide confirms the reaction with sulfhydryl 
groups. 
Polymer in CDCl3
NAEM-Polymer  
Conjugate in CDCl3
CREKA-Polymer  
Conjugate in Acetone-d6
CREKA in D2O
 63 
 
 
 
 
 
 
Figure 4-10 HPLC chromatograms of quantitative conjugation reaction between 
CREKA and NAEM conjugate. 
When NAEM functionalized polymer is reacted with peptide (CREKA, r.t. 
= 3.7 min), a new peak is formed (r.t. = 6.7 min). The peptide is 
consumed, and only one product peak is observed. This product peak 
forms within the first hour of reaction and remains unchanged thereafter. 
These observations indicate the quantitative incorporation of the peptide 
unit into the polymer. 
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Table 4-1  Summary of Block and Statistical Copolymers used for Analysis of 
Untargeted Polymers 
 
Polymer Polymer Type 
TBMA / 
PEGMA 
Degree of 
Deprotection 
(NMR) 
MN, CAL MN, GPCa PDGPCa 
NP No Polymer N/A - - - - 
EPC 
Phospholipid 
N/A - 760* - - 
(Egg Phosphatidylcholine) 
PAA Homopolymer N/A - - - < 2* 
PTBMA Homopolymer N/A 0% 4,240 3,960 1.28 (0.01) 
PMAA Homopolymer N/A 100% 2,570 2,400 1.28 
0% B Block Copolymer 3.1:1 0% 9,320 13,200 (384) 1.13 (0.01) 
PTBMA-40 Homopolymer N/A 40% 3,640 3,380 1.28 
50% B Block Copolymer 3.1:1 50% 8,620 12,500 1.20 (0.04) 
80% B Block Copolymer 3.1:1 80% 8,250 11,700 1.29 (0.01) 
0% S Statistical Copolymer 2.7:1 0% 7,090 11,000 (442) 1.27 (0.05) 
80% S Statistical Copolymer 2.7:1 80% 6,240 10,200 1.28 (0.01) 
* Vendor data 
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Table 4-2  Polymers used for Evaluation of Targeted Polymer Analysis 
 
Polymer 
Name 
Functional 
Group 
Number of 
Functional 
Groups 
Chain 
Length 
Number 
of MA 
Units 
Number 
of PEG 
Units 
MA/PEG 
Ratio 
PEG 
Chain 
Length 
Molecular 
Weight 
P1-Pro - - 18.4 15.9 2.5 6.5 1,100 5,200 
P1 - - 18.4 15.9 2.5 6.5 1,100 4,300 
P1-N NAEM - 18.4 15.9 2.5 6.5 1,100 6,200 
P1-L CREKA 2.3 18.4 15.9 2.5 6.5 1,100 9,300 
P1-H CREKA 6.7 18.4 15.9 2.5 6.5 1,100 14,400 
P1-S CAERK 2.4 18.4 15.9 2.5 6.5 1,100 9,300 
P2-Pro - - 18.2 16.0 2.2 7.3 300 3,100 
P2 - - 18.2 16.0 2.2 7.3 300 2,200 
P2-N NAEM - 18.2 16.0 2.2 7.3 300 4,200 
P2-L CREKA 2.4 18.2 16.0 2.2 7.3 300 7,300 
P2-H CREKA 7.4 18.2 16.0 2.2 7.3 300 12,800 
P2-S CAERK 2.4 18.2 16.0 2.2 7.3 300 7,300 
P3-Pro - - 30.9 26.7 4.2 6.4 1,100 8,700 
P3 - - 30.9 26.7 4.2 6.4 1,100 7,300 
P3-N NAEM - 30.9 26.7 4.2 6.4 1,100 10,500 
P3-L1 CREKA 2.2 30.9 26.7 4.2 6.4 1,100 14,800 
P3-H CREKA 6.2 30.9 26.7 4.2 6.4 1,100 21,000 
P3-S CAERK 2.2 30.9 26.7 4.2 6.4 1,100 14,800 
P4-Pro - - 22.1 17.5 4.6 3.8 300 4,300 
P4 - - 22.1 17.5 4.6 3.8 300 3,300 
P4-N NAEM - 22.1 17.5 4.6 3.8 300 5,400 
P4-L CREKA 2.3 22.1 17.5 4.6 3.8 300 8,700 
P4-H CREKA 7.1 22.1 17.5 4.6 3.8 300 14,200 
P4-S CAERK 2.3 22.1 17.5 4.6 3.8 300 8,600 
PMAA-Pro - - 18.3 18.3 0.0 N/A N/A 2,600 
PMAA - - 18.3 18.3 0.0 N/A N/A 1,600 
PMAA-N NAEM - 18.3 18.3 0.0 N/A N/A 3,800 
PMAA-L CREKA 1.9 18.3 18.3 0.0 N/A N/A 5,800 
PMAA-H CREKA 5.8 18.3 18.3 0.0 N/A N/A 10,800 
PMAA-S CAERK 2.0 18.3 18.3 0.0 N/A N/A 7,800 
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CHAPTER 5. BLOCKADE OF NON-SPECIFIC PROTEIN ADSORPTION AND 
CELLULAR ATTACHMENT WITH UNTARGETED POLYMERIC BIOMATERIALS 
 
Based on studies published in:  
John M Medley, Eric J Beane, S K C Sundararaj, Eugene Kaplan, David A Puleo, 
Thomas D Dziubla. “Block copolymers for the rational design of self-forming 
postsurgical adhesion barriers.” Acta Biomaterialia, 2010, 6 (1): p. 72 [5]. Used 
with permission. 
 
5.1. Introduction 
Following abdominal surgery, the internal wound healing process can result in 
fibrous tissue deposits that connect adjacent tissues, leading to the formation of post-
surgical adhesions[1, 2]. While often asymptomatic, these post-surgical adhesions (PSAs) 
can lead to serious problems, including bowel obstructions, chronic pain, and infertility. 
In the United States, an estimated 440,000 adhesiolysis surgeries are conducted annually 
to correct issues arising from the formation of PSAs [3, 4]. 
Of all the strategies used to prevent PSA formation, physical barriers have been 
the most successful [5]. While solid barriers are often employed (such as hyaluronic acid 
derivatives), some success has been demonstrated with liquid materials such as 
polyethylene glycol (PEG) and phospholipids [4, 6-11]. In order to obtain next generation 
improvements upon this technology, the limiting factors must be overcome, including (1) 
inability to identify pro-adhesive sites, (2) general difficulty in barrier application, and (3) 
limited applicability to laparoscopic surgeries. These pro-adhesive sites are often 
characterized by denuded basement membrane or other damaged tissues and fibrin 
exudates, which can contain highly adhesive, positively charged domains. It is 
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hypothesized that an aqueous polymer solution, which can naturally target these pro-
adhesive sites and form a barrier, will inhibit PSA formation. Adhesion formation occurs 
when the fibrin gel matrix (FGM) bridges apposing tissues and remains in place, 
providing a scaffold for subsequent scar formation [12-15]. By retarding protein 
adsorption and cellular attachment at damaged sites, it is believed that the rate of FGM 
thickening will decrease, while the rate of fibrinolysis will remain unchanged. This 
should prevent the FGM from remaining in place long enough to promote PSA formation 
and therefore should allow normal healing to occur at the site of damaged tissues. 
Although the mechanism of interaction with the damaged tissues is different, 
investigation of similar materials with a positive charge has shown promising results in 
the prevention of PSAs [5, 16]. 
To design a material for testing this hypothesis, it is necessary to develop clear 
structure-function relationships to optimize polymer barrier performance. In this work, a 
living polymerization scheme and a data-rich analytical method were developed to obtain 
these molecular structure-function relationships, allowing for the further development of 
targetable post-surgical adhesion barriers. Group Transfer Polymerization (GTP) was 
used to synthesize copolymers of methacrylic acid (MA), t-butylmethacrylate (TBMA), 
and poly(ethylene glycol-methacrylate) (MN=1100, PEGMA1100) with well controlled 
structures for investigation as adhesion barriers. The reaction scheme was designed to 
facilitate precise control of the molecular weight and charge density of the final polymer. 
Methacrylic acid was selected as the monomer for the polymer backbone due to its 
demonstrated biocompatibility in a variety of applications and future amenability towards 
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functionalization [17-20]. PEG was used to inhibit protein-interaction with the adsorbed 
polymer layer [21-26].  
Rapid, quantitative relationships between polymer properties and function were 
obtained using quartz crystal microgravimetry with dissipation (QCM-D) coupled with 
kinetic analysis. From this analysis, it was found that these materials adsorb rapidly to 
charged surfaces and reduce subsequent non-specific protein adsorption. Depending on 
the molecular architecture and charge density of the polymer, this polymeric material 
exhibited up to an 81% reduction in bovine serum albumin (BSA) adsorption. The 
existence of two competing mechanisms for polymer adsorption, as observed in both 
energy dissipation analysis from the QCM-D and with variable angle spectroscopic 
ellipsometry (VASE), provides an unanticipated means to control the adsorption of these 
materials to surfaces. The protective properties of charge-targeted polymers were 
confirmed with an in vitro assay of cell-substrate binding. It is anticipated that further 
understanding of the adsorption mechanisms will allow the rational development of 
polymeric biomaterials for the prevention of PSAs. 
5.2. Materials and Methods 
5.2.1. Quartz Crystal Substrate Preparation 
A model surface consisting of amine terminated self-assembled monolayers 
(SAM) on gold-coated quartz sensor crystals (Q-Sense) was employed for the evaluation 
of surface adsorption and protein resistance effects. These SAM surfaces were generated 
immediately prior to testing using a modification of previously described techniques 
[201-203]. Prior to SAM formation, crystals were cleaned by immersion in an ammonium 
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peroxide solution for 5 minutes at 70 oC, rinsed with deionized water, and dried under a 
stream of inert gas [204]. Immediately after cleaning, the crystals were immersed in vials 
in alkaline 1 mM 11-amino-1-undecanethiol, purged with argon, sealed, and protected 
from light. After allowing the SAM formation to proceed overnight, the crystals were 
removed from the solution, rinsed repeatedly with neutral ethanol and acidic ethanol, and 
dried with a stream of inert gas.  
5.2.2. QCM Analysis 
The functional properties of the materials were evaluated by monitoring the 
sequential adsorption of the polymers and BSA to model surfaces. This technique takes 
advantage of the fact that the resonant frequency of a quartz crystal varies as mass is 
adsorbed onto the surface. By monitoring the resonance frequency of the crystal as it is 
exposed to a series of solutions containing analytes of interest, it is possible to observe 
the adsorption of nanogram scale changes in mass. All experiments were conducted in a 
Quartz Crystal Microbalance (Q-Sense E4) using standard Teflon® and Tygon® tubing 
materials with a flow rate of 250 µL/min. After installing a crystal in the flow module, 
the sensor crystal was rinsed sequentially with acidic ethanol, neutral ethanol, deionized 
water, and PBS solution to ensure that all unbound aminothiol was removed from the 
crystal and to establish a flat baseline (less than 0.25 Hz/min drift).  The change in 
frequency and energy dissipation were measured as a function of time to monitor the 
adsorption of the polymer from solution (1.0 mg/mL in PBS).  
A typical experimental QCM-D curve is presented in Figure 5-1. First, a polymer 
solution was flowed over the crystal surface, resulting in a decrease in resonance 
frequency until saturation of the surface was achieved. After this saturation point was 
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obtained, a pure buffer solution was flowed over the crystal to remove the “loosely” 
bound polymer fraction. To test the barrier function of the adsorbed polymer layer, a 
solution of BSA was then flowed over the surface until saturation was obtained. 
Following the saturated binding, a final pure buffer solution was flowed to calculate the 
amount of BSA strongly adsorbed onto the surface. Using the Sauerbrey model, which 
neglects viscous effects and assumes that the adsorbed layer is rigid, the mass of 
adsorbed layer was calculated using Equation (5-1). In this expression, C is a constant 
characteristic of the Q-Sense E4system (17.7 ng/cm2 Hz), and n is the number of the 
harmonic overtone being considered [205]. Since the change in energy dissipation was 
small in all measurements (<1*10-6 per 10 Hz frequency change), the Sauerbrey model 
was assumed to provide an accurate description of the adsorbed mass for all analyses 
with the usual caveat that the QCM measurement also includes any water bound or 
coupled to the surface [206]. A representative curve of specific mass adsorption is shown 
in Figure 5-2. 
 
Δm = − C∆fn     (5-1) 
 
A simple kinetic model of the adsorption and desorption phenomena was 
employed to compare the kinetics of the interactions of the materials with model surfaces. 
If it is assumed that there are a discrete number of uniform surface sites available for 
reversible adsorption from solution, it is possible to visualize the adsorption phenomenon 
as shown in Figure 5-3. If it is further assumed that no interaction occurs between 
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adsorbed molecules or between molecules on the surface with molecules in solution, this 
Langmuir-type adsorption can be described by Equations (5-2) – (5-6): 
 [SA] = α
β
�1 − e−βt�   (5-2) [SA]max = αβ    (5-3) t1 2� = ln (2)β     (5-4) 
α = k1[A][S]0    (5-5) 
β = k1[A] + k2   (5-6) 
 
In these expressions, [SA] is the concentration of adsorbate on the surface, 
[SA]max is the maximum observed concentration observed, t½ is the half-life of the 
adsorption process, [A] is the solution concentration of the adsorbate, [S]0 is the total 
number of surface sites, and k1 and k2 are the kinetic coefficients of adsorption and 
desorption, respectively. Using a least squares analysis, these equations were fit to the 
experimental data, and [SA]max and t½ were evaluated for each adsorption event. The 
observed data follow this model very closely for all of the materials examined, with the 
notable exception of EPC. This material exhibited linear kinetics with no maximum 
adsorption; as a result, the kinetic half-life was not determined for this material. 
Since material was often observed desorbing from the surface after switching 
back to a buffer solution, this desorption event was also modeled as shown in Figure 5-4. 
Since [A] is equal to zero in this case, this desorption phenomenon is described by 
Equations (5-7) – (5-8): 
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[SA] = [SA]loose �e−k2t�  (5-7) t1 2� = ln (2)k2      (5-8) 
 
The amount of material strongly bound to the surface, [SA]bound, is taken as the 
difference in the amount initially adsorbed, [SA]max, and the amount observed desorbing, 
[SA]loose.  
This analysis assumes a perfect laminar flow over the crystal surface. Although 
the flow chamber was designed to provide a very rapid exchange of solutions with 
minimal mixing, there is a brief induction period when the observed kinetic rate may be 
retarded by mixing within the flow cell [207]. At a flow rate of 250 µL/min and a 
chamber volume of 40 µL, this induction time is 10 seconds. While this limits our ability 
to obtain absolute kinetics in very fast processes, relative kinetic behavior could still be 
obtained. 
5.2.3. Variable Angle Spectroscopic Ellipsometry 
Gold QCM crystals were prepared using the same protocol for SAM formation 
and polymer adsorption and subjected to variable angle spectroscopic ellipsometry 
(VASE) using the M-2000V variable angle spectroscopic ellipsometer (J. A. Woolam 
Co.). Wavelengths from 370 nm to 1700 nm were measured at 45o to 75o in 5o 
increments. Data was analyzed using the WVASE32® software package in a stepwise 
fashion. First, a bare gold substrate was analyzed to determine the optical constants (n 
and k). Then, the amine terminated SAM was measured and the data fitted as a Cauchy 
film to determine the film thickness. Finally, the polymer samples were measured. Using 
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the previously fitted valued from the substrate and the SAM layer, the thickness of the 
polymer layer was fitted as an additional Cauchy layer [208].  
5.2.4. Cell Attachment Studies 
In order to test the anti-cellular adhesive properties of these materials, a 
complementary cell culture study was carried out using the mouse mesenchymal D1 cell 
line (ATCC CRL-12424) in 24-well tissue culture plates. This pluripotent cell line was 
selected due to its strong adherence to charged surfaces and wound healing components 
(e.g., collagen I and fibrin) [209-212]. Wells were coated with poly(L-lysine) (250 µL 0.1 
mg/mL in sterile PBS) and incubated at room temperature for 2 hours. After rinsing the 
wells 3 times with sterile PBS, polymer solutions were added (200 µL 1.0 mg/mL in 
sterile PBS) and incubated at room temperature for 2 hours. The polymer solutions were 
removed from the wells, and each well was rinsed 3 times with sterile PBS. Finally, each 
well was seeded with 250,000 cells in Dulbecco’s Modified Eagle Medium (DMEM, 
HyClone Laboratories) containing 10% fetal bovine serum (GIBCO/Invitrogen) and 
incubated at 37 oC for two hours. Untreated tissue culture polystyrene (TCP) and PLL-
coated TCP were employed, and a minimum of 6 replicates were studied for each 
material. 
After incubation, unattached cells were removed from the wells by rinsing twice 
with sterile PBS. Representative images of the cells were obtained using an inverted 
phase contrast microscope. The cells remaining on the surface after rinsing were lysed by 
sonication in high salt solution (0.05 M NaH2PO4, 2 M NaCl, and 2 mM EDTA). DNA 
contents, measured using Hoechst 33258 stain, were used to quantify the number of cells 
in each well [213-214].  In short, Hoechst 33258 (final concentration, 0.5 µg/ml, Sigma) 
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was allowed to react with lysates in the dark for 10 minutes, after which fluorescence was 
measured (• ex = 356 nm and • em = 458 nm).  An exponential calibration curve was 
prepared using samples with known cell counts (0 – 200,000 cells). After measuring the 
fluorescence of each well, this calibration was employed to determine the number of cells 
attached in each well. Sample wells whose fluorescence indicated > 250,000 cells were 
neglected as spurious measurements, since such readings would correspond to greater 
than 100% cellular attachment.  
5.2.5. Statistical Evaluation 
Statistical relevance was determined by performing analysis of variance followed 
by a Sidak pair wise post-hoc analysis using Minitab 15. Differences at greater than 90% 
and 95% confidence are reported, with statistical significance being considered at the 
95% level.  
5.3. Results  
5.3.1. Polymer Binding and Release from Amine-terminated SAM Surfaces 
Based upon analysis of attachment rates (on rates) of polymer adsorption (Figure 
5-5), there was no statistical difference among the polymer samples. While the on rates 
varied greatly between runs, detachment rates (off rates) were much more consistent. As 
the fraction of acidic groups in the polymer increased from 0% to 80% for the PAA 
copolymers, polymer adsorption to the charged surface varied from 211 – 468 ng/cm2 
(Figure 5-6). A statistically significant maximum in [SA]max was found at a charge 
density of 50%. The 40% deprotected PTBMA showed significantly less specific mass 
adsorption that the 50% block copolymer. As PBS was flowed over the surface and 
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polymer desorption occurred, sample differences between all charged diblock polymers 
were attenuated. PAA, 40% deprotected PTBMA, and 0% deprotected block copolymer 
possessed the lowest degree of surface coverage.  
There was also a noticeable difference in the mechanism of binding. Figure 5-7 
shows plots of the energy dissipation change (• D) versus the mass adsorbed. The slope 
of these curves increased with charge density for the PAA copolymers. The final values 
of the ratio, �
∆D
∆m�), shown in Figure 5-8, provide a means to evaluate the conformation of 
the polymer adsorbed to the surface [207, 215]. A lower value indicates a relatively small 
amount of energy dissipation per unit mass, while a higher value reflects increasing levels 
of energy dissipation per unit mass. A low value indicates a relatively rigid, compact 
adsorbed layer, while a higher value for this ratio indicates an adsorbed layer that extends 
further away from the surface [207].  
5.3.2. Surface Film Thickness 
Variable angle spectroscopic ellipsometry was performed to verify the mass 
absorption trends observed by QCM.  The results of the VASE analysis are presented in 
Figure 5-9. By measuring multiple wavelengths and angles, it was possible to probe the 
surface multiple times and obtain an accurate measurement of the film thickness. The 
PAA polymer exhibited a thickness of 109.3 Å, while the hydrophobic block copolymer 
and the EPC film thicknesses were 80.5 Å and 48.4 Å, respectively. The remaining 
materials showed ellipsometric thicknesses of 1.4 Å to 30.8 Å. Due to the high degree of 
variance in the data, no statistically significant differences were identified.  
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5.3.3. Blockade of Protein Adsorption by Diblock Copolymers 
Unlike with polymer adsorption, there was a distinct change in kinetics of protein 
binding among samples (see Figure 5-10). The half-life of protein adsorption was lowest 
for the surfaces with relatively hydrophobic coatings (PMAA, EPC, PTBMA-40) and for 
the uncoated SAM surface, suggesting the greatest affinity of BSA. The more hydrophilic 
PMAA copolymers and PAA control possessed the slowest binding rates of all materials 
tested. There was no statistical difference in the kinetics of the protein adsorption for 
diblock copolymer coated surfaces. As expected, the uncoated charge surface possessed 
the greatest degree of protein binding (Figure 5-11). Of all test samples, 0% block 
copolymer possessed the best blocking ability of all tested polymers (Figure 5-12). It is 
possible that the 80% statistical copolymer sample possessed equivalent surface blocking 
capacity; however, variability in the data makes this analysis inconclusive. As specific 
and non-specific protein adsorption interactions are integral precursors to the formation 
of a post-surgical adhesions, it is believed that the ability to delay this event serves as one 
measure of a material’s ability to interrupt PSA formation.  
5.3.4. Suppression of Cellular Attachment to PLL Coated Surfaces by Diblock 
Copolymers  
Measurement of cell attachment was used to determine whether previously 
observed differences in polymer binding to surfaces and protein adsorption to polymers 
translate to reduced cell-surface interactions.  In order to make meaningful comparisons 
with the QCM data and to mimic the positively charged basement membrane, PLL was 
used as a control surface. Close observation of the wells revealed significant 
heterogeneity and pooling of cells in the well edges, suggesting that inadequate washing 
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was used to remove all unbound cells. Representative images of the wells, taken from the 
same location in each well, are shown in Figure 5-13. TCP and PLL mediated the 
greatest level of cell attachment, with nearly full surface coverage noted. The PAA, 0% 
block, EPC, PTBMA-40, and 80% block each appeared to have a slightly lower level 
cellular attachment than the controls.  The 50% block, PMAA, and 80% statistical 
copolymer treated wells demonstrated a large reduction in the apparent number of cells 
attached during the 2 hour incubation period. 
Quantitative results for cell attachment are shown in Figure 5-14.  Due to the 
wide variability contributed by one outlier, no statistically significant differences were 
observed. Some trends, however, were observed. When copolymers possessed a negative 
charge, i.e., 50% block, 80% block, and 80% statistical, suppression in cellular 
attachment, compared to PLL controls, was observed.  
5.4. Discussion  
In order for a material to be applicable for use as a prophylactic PSA treatment, 
several requirements must be met. First, the material must be amenable to use within the 
body, including biodegradability and renal clearance capacity. PEG and PMAA both 
have well characterized biocompatibility and are not expected to cause adverse 
biochemical interactions. Using GTP, it is possible to synthesize copolymers of PEG and 
PMAA with precisely controlled molecular composition. This polymerization technique 
also facilitates the synthesis of block copolymers to control the spatial orientation of the 
adsorbing and protective moieties within the molecule. Relying on ester bonds to attach 
the pendant PEG groups to the PMAA backbone, these materials are designed to be 
susceptible to both enzymatic and hydrolytic degradation. To ensure ultimate elimination 
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of the polymer, the maximum molecular weight of the synthesized materials was 
designed to be less than 50 kDa [134, 216]. 
The primary method to assess PSA prevention technologies has been through the 
use of animal models [5, 217]. Since these studies are costly, time consuming, and have 
ethical implications, it is desirable to test materials in vitro prior to initiation of animal 
studies.  QCM-D analysis of polymer and protein interactions with model surfaces 
provides a data-rich method of analysis, affording data on polymer surface affinity, 
barrier stability and performance, and absorbed layer rigidity and thickness. The simple 
amine-terminated SAM model surface allows a reproducible, high throughput method to 
assess these materials, aiding in the development of the method, and providing a platform 
for testing the charge based targeting of the diblock poly(methacrylic acid) copolymers. 
Such a system provides the opportunity for rapid evaluation and optimization during 
further investigations of potential barrier materials. 
The power of this method was realized upon the observation of multiple surface 
adsorption mechanisms occurring as a result of changes in polymeric charge density. In 
these experiments, the materials with higher concentrations of acidic groups led to a 
thicker, more loosely bound layer adsorbed to the substrate. This was likely a result of the 
negatively charged acid groups strongly interacting with the positively charged surface 
and the grafted PEG block being forced into a more extended conformation from the 
surface. As charge density decreased, a second adsorption mechanism was observed. 
Although the exact nature of the interactions is unknown at this time, it is believed that 
they result either from hydrogen bonding between the charged surface and PEG chains or 
from hydrophobic interactions of the uncharged polymer with domains of imperfect SAM 
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formation that result in the exposure of aminothiol chains to the solution. Both of these 
proposed mechanisms would result in the development of a more tightly bound polymer 
layer as multiple points of the polymer chain interact with the surface. This is likely to 
result in a much more random adsorption to the surface with PEG chains in a less brush-
like conformation. The phospholipids, which are expected to form a lamellar structure, 
also form a loosely bound surface layer. 
As has been observed in numerous studies, QCM cannot distinguish between 
adsorbed polymer mass and polymer mass plus bound water [218-220]. In order to 
determine the mass of bound water in the adsorbed layer measured by QCM, the values 
obtained from QCM were compared with the results obtained from VASE. Assuming a 
nominal polymer density of 1.1 g/cm3, the amount of water bound in the surface layer can 
be estimated. The surface layers formed by the most hydrophilic copolymers (50% block, 
80% block, and 80% statistical) contain in excess of 90% water. The more hydrophobic 
materials (PTBMA-40, 0% block copolymer, and EPC) form surface layers with 
approximately 50% water. These observations support the two mechanisms of surface 
adsorption and surface conformation. The PAA layer indicated a greater surface mass 
when measured by ellipsometry and, coupled with the high standard deviation associated 
with this measurement, suggests a high degree of non-uniformity and variability within 
the PAA surface film.   
The most surprising finding of this work was the performance of the hydrophobic, 
protected polymers. These materials possessed the lowest degree of polymer binding, but 
they had the best ability to block subsequent BSA adsorption in the QCM-D analysis. 
The two competing mechanisms observed during polymer adsorption can explain the 
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unexpectedly strong performance of the t-butyl protected polymer. While adsorption to 
the surface via electrostatic interactions was not possible, the multiple points of 
interaction between the polymer and the surface resulted in a compact layer of strongly 
bound material. This material occupies sites where BSA binding would potentially occur 
and therefore effectively prevented nonspecific adsorption of proteins to the surface. 
Indeed, this result was found to be a unique feature of the QCM-D and not replicated in 
the cell culture studies, where the 0% hydrolyzed polymer possessed no ability to inhibit 
cellular attachment to PLL.  The complex, multicomponent makeup of cell culture 
medium compared to BSA-only solutions may explain this apparent discrepancy.  
No significant differences were observed between the performances of the 
statistical and block copolymers. It may be expected that the bifunctional composition of 
the block copolymer would result in stronger binding to the model surface and an 
increase in the extended character of the PEG moieties. These differences in polymer 
architecture, however, have no significant impact on the amount of polymer adsorbed to 
the model surface or the kinetics of adsorption. This suggests that, when electrostatic 
forces exist, they dominate polymer-surface interactions. In addition, the fact that the 
rigidity of the adsorbed layer and its ability to resist protein adsorption was independent 
of the configuration of the monomeric units comprising the polymer (i.e., block vs. 
statistical copolymer) suggests that protein-resistant conformation can be achieved 
without a high relative concentration of PEG units.  
It appears that there is a point at which both of these proposed mechanisms 
contribute significantly to the adsorption of polymer. The 50% deprotected block 
copolymer exhibited a statistically significant increase for material initially adsorbed to 
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the surface, but upon rinsing with PBS, this difference was no longer seen. Consideration 
of this observation and of the protein blockade properties that closely mimic the more 
highly charged species suggests that, after an initial competition between the two binding 
mechanisms, a conformation based on charge affinity was obtained. This hypothesis can 
be tested by varying the pH of the adsorption conditions and determining the relative 
contributions of the competing mechanisms. It is anticipated that, once more thoroughly 
understood, these competitive mechanisms may be exploited to provide an additional 
measure of control over the polymer properties. 
The PAA control used in these experiments demonstrated a unique property that 
results from the absence of PEG groups. While this polymer rapidly formed a strongly 
bound surface layer, its thickness suggests that, rather than forming a molecular 
monolayer on the surface, multiple layers of molecules were deposited. The resulting 
layer inhibited protein adsorption kinetics, as the BSA molecules were forced to permeate 
this more viscous PAA layer in order to bind to the surface. PMAA and PTBMA-40 form 
similar surface layers; but, due to their increased hydrophobicity, do not retard the 
adsorption of BSA.  
In cell culture, when in the presence of competing negatively and positively 
charged serum proteins, which could detach the bound polymer, in vitro studies 
confirmed that the synthetic copolymers can bind to positively charged substrates and 
significantly reduce cellular attachment. The results of the cell culture studies suggest 
that the 50% block and 80% statistical copolymer were most effective, while QCM data 
indicated the largest protein blockade with the 0% block and 80% statistical copolymers. 
It is believed that this discrepancy results from the nonspecific binding mechanism of the 
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0% block copolymer to the surface, which is incapable of suppressing cellular attachment 
in more complex serum-containing solutions. As indicated by the cell attachment studies 
PMAA, PTBMA-40, PAA and EPC all failed to inhibit cell attachment. Indeed, these 
materials likely only exchanged the surface charge from positive to negative, and the 
pluripotent mesenchymal cells can adhere to both of these charges [209, 212]. This result 
is of paramount importance when designing a material that can suppress tissue adhesion. 
While the proliferation of cells like the mesenchymal D1 cells are desired in wound 
healing, they serve as an easy to use reference for strong cell adhesion. By designing a 
material that can suppress all cells types from attaching to the surface of a damaged 
organ, it is believe that more time would be allowed for sub surface wound healing to 
occur, allowing for island implantation and reformation of the epithelial layer without 
permitting scar tissue bridging.  Future in vivo studies will be needed to verify this 
hypothesis. 
5.5. Conclusion 
Group transfer polymerization was successfully employed to create block 
copolymers with varying charge density. The polymers adsorbed strongly to model SAM 
surfaces via two competing mechanisms; the relative importance of each of these 
mechanisms is a function of the charge density along the final polymer backbone. The 
resulting self-formed polymer layer strongly resisted non-specific protein adsorption and 
may be exploited to develop a new treatment strategy for the prevention of post-surgical 
adhesions. The control afforded by the polymerization method of these synthetic 
materials allows their properties to be tailored to optimize their function. Additional 
investigations will focus on developing a deeper understanding of the mechanism and 
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thermodynamics of the observed polymer adsorption phenomena as we move to more 
biologically relevant model surfaces and confirm the relationship observed with 
appropriate in vivo models of surgical adhesion formation. 
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Figure 5-1 Raw data (frequency response) from QCM measurement. 
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Figure 5-2  Specific mass adsorption based on Sauerbrey model, which assumes a 
linear fit between frequency response and adsorbed mass. 
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Figure 5-3 Kinetic fit of BSA adsorption to model substrate after preadsorption with 
80% block copolymer. 
[SA]max = 152.1 ng/cm2 and t½ = 20.9 s.  
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Figure 5-4 Kinetic model fit of BSA desorption from model substrate after 
preadsorption with 80% block copolymer. 
[SA]0 = 21.9 ng/cm
2 and t½ = 27.8 s. 
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Figure 5-5 Polymer adsorption kinetics.  
No significant differences was noted in the half-life for polymer 
adsorption (grey bars) and desorption (white bars) from solution onto the 
QCM surface.  
*  PTBMA-40 was prepared at 1.0 mg/mL, but was only partially 
soluble. Insoluble material was removed by filtration and the saturated 
PTBMA-40 solution was used for analysis. 
**  Insufficient PAA data for meaningful comparison. 
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Figure 5-6  Maximum specific mass adsorption, [SA]max, and specific mass of tightly 
bound polymer, [SA]bound.  
Statistical comparisons are given: 90% confidence compared to 0 B (a), 
95% confidence compared to 0 B (b), 95% confidence compared to 
PTMBA-40 (d), 90% confidence compared to 50 B (e), 95% confidence 
compared to 50 B (f), 90% confidence compared to PAA (h), and 95% 
confidence compared to 80 B  (n). (n = 3 – 5, M ± SE) 
*  PTBMA-40 was prepared at 1.0 mg/mL, but was only partially 
soluble. Insoluble material was removed by filtration and the saturated 
PTBMA-40 solution was used for analysis.  
**  Insufficient PAA data for meaningful comparison. 
†  EPC exhibited linear kinetics with no desorption. The mass reported is 
the mass adsorbed to the surface after 200 s of adsorption in QCM. 
Not included in statistical analysis. 
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Figure 5-7 Dissipation change as a function of adsorbed mass for polymer adsorption 
phenomena. 
The slope of the curve represents the relative rigidity of the adsorbed 
layer, with a steeper slope indicating a less rigid adsorbed layer. 
*  PTBMA-40 was prepared at 1.0 mg/mL, but was only partially 
soluble. Insoluble material was removed by filtration and the saturated 
PTBMA-40 solution was used for analysis. 
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Figure 5-8 Terminal value of the of the energy dissipation change versus adsorbed 
mass. 
The observed trend indicates that, as the charge density along the polymer 
increases, the polymer extends farther from the surface, indicating a more 
extended PEG conformation. Statistical comparisons are given: 95% 
confidence compared to 0 B (b), 95% confidence compared to PTMBA-40 
(d), 90% confidence compared to 50 B (e), and 95% confidence compared 
to 50 B (f). (n = 3, M ± SE)  
*  PTBMA-40 was prepared at 1.0 mg/mL, but was only partially 
soluble. Insoluble material was removed by filtration and the saturated 
PTBMA-40 solution was used for analysis. 
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Figure 5-9  Film thickness measured by variable angle spectroscopic ellipsometry. 
No significant differences were observed.. (n = 2 – 3, M ± SE) 
*  PTBMA-40 was prepared at 1.0 mg/mL, but was only partially 
soluble. Insoluble material was removed by filtration and the saturated 
PTBMA-40 solution was used for analysis. 
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Figure 5-10 Kinetics of BSA adsorption from solution. 
 Unlike polymer adsorption, half-life for polymer adsorption possessed 
statistically significant differences suggesting a change in the kinetic 
accessibility of protein to the material surface. Statistical comparisons are 
given: 90% confidence compared to 50 B (e), 90% confidence compared 
to PAA (h), 95% confidence compared to PAA (i), 95% confidence 
compared to 80B (n). (n = 3 – 5, M ± SE) 
*  PTBMA-40 was prepared at 1.0 mg/mL, but was only partially 
soluble. Insoluble material was removed by filtration and the saturated 
PTBMA-40 solution was used for analysis.  
** Insufficient NP, PMAA, and PTBMA-40 data for meaningful 
comparison. 
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Figure 5-11 Mass of BSA adsorbed from solution. 
All polymers possessed an ability to reduce the level of protein adsorption 
as determined by maximum specific mass adsorption,[SA]max, and specific 
mass of tightly bound polymer,[SA]bound.  
Best blockage was achieved by the uncharged diblock copolymer. 
Statistical comparisons are given: 90% confidence compared to 0 B (a), 
95% confidence compared to 0 B (b), 95% confidence compared to 
PTMBA-40 (d), 90% confidence compared to NP (o), and 95% confidence 
compared to NP (p). (n = 3 – 5, M ± SE) 
*  PTBMA-40 was prepared at 1.0 mg/mL, but was only partially 
soluble. Insoluble material was removed by filtration and the saturated 
PTBMA-40 solution was used for analysis. 
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Figure 5-12  Percent protein blockade compared to control. 
Statistical comparisons are given: 90% confidence compared to 0 B, 90% 
confidence compared to NP (o), and 95% confidence compared to NP (p). 
(n = 3 – 4, M ± SE) 
*  PTBMA-40 was prepared at 1.0 mg/mL, but was only partially 
soluble. Insoluble material was removed by filtration and the saturated 
PTBMA-40 solution was used for analysis.  
** Insufficient PMAA and PTBMA-40 data for meaningful comparison. 
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Figure 5-13 Cell attachment to polymer-coated surfaces.   
Representative images were obtained after incubating for 2 hours, after 
which nonadherent cells were removed.  
*  PTBMA-40 was prepared at 1.0 mg/mL, but was only partially 
soluble. Insoluble material was removed by filtration and the saturated 
PTBMA-40 solution was used for analysis. 
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Figure 5-14 Average degree of cellular attachment relative to the PLL control.  
Cell numbers were determined using a fluorometric DNA assay (n = 4 – 
11, M ± SE).  
*  PTBMA-40 was prepared at 1.0 mg/mL, but was only partially 
soluble. Insoluble material was removed by filtration and the saturated 
PTBMA-40 solution was used for analysis. 
 
 
0%
25%
50%
75%
100%
125%
150%
175%
T
C
P
P
L
L
PA
A
P
M
A
A
E
P
C
0%
 B
50%
 B
80%
 B
80%
 S
P
T
B
M
A
-40*
C
el
lu
la
r 
A
tt
ac
h
m
en
t 
(N
o
rm
al
iz
ed
 t
o
 P
L
L
)
Untreated
Samples
Treated Samples
 98 
 
 
CHAPTER 6.  DISRUPTION OF FIBRIN GEL MATRIX FORMATION BY 
TARGETED POLYMERS 
 
6.1 Introduction 
As has been described, the fibrin gel matrix (FGM) is a critical component in the 
formation of post surgical adhesions. Consisting primarily of fibrin and a mixture of 
extracellular matrix components including  fibronectin, hyaluronic acid, 
glucosaminoglycans and proteoglycans, the FGM can bridge apposing tissues in the body 
and lead to the formation of PSAs [1, 8, 221]. One of the main goals of this research is to 
develop a material that will interrupt FGM formation and disrupt the cascade of events 
that leads to PSA formation. In the previous chapter, the ability of synthetic block 
copolymers to adsorb to charged surfaces and block non-specific protein adsorption was 
studied.  
In order to test these materials in a more biologically relevant manner, this 
investigation focuses on the ability to target polymers to fibrin coated surfaces and retard 
the subsequent propagation of the fibrin gel formation. By directing these barrier 
materials to the site of tissue damage, these targeted materials are expected to provide 
two unique advantages. First, this approach should facilitate the protection of proadhesive 
sites that are difficult to identify or are inaccessible. Second, the presence of multiple 
specific interactions with the damaged tissue, the resulting barriers should provide 
enhanced durability over non-targeted materials. 
It was hypothesized that the molecular structure can be tailored to optimize the 
adsorption of polymeric biomaterials to pro-adhesive sites on the tissue surface and 
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attenuate the formation of post surgical adhesions. In order to test this hypothesis, block 
copolymers were synthesized with highly controlled molecular architectures. Since PEG 
was incorporated into the polymer structure for its well characterized anti-adhesive 
properties, the PEG structure in the polymers were varied by using PEGMA monomer 
(MN = 300 and MN = 1,100).  In addition, the number of PEG chains in the polymer was 
varied to study the impact of total PEG content. Finally, the effect of targeting peptides in 
the polymer structure was investigated by varying both nature and the number of these 
units in each polymer molecule.  
After completion of the experiments, the resulting data set was statistically 
analyzed to assess the relative importance of these factors in the polymers’ ability to 
target fibrin and to retard various aspects of FGM formation. When statistical differences 
were observed in the data for an experiment, post hoc pairwise Sidak comparisons were 
used to quantify these differences. Finally, multivariate linear regression was employed 
to assess the impact of the changes in molecular architecture on the results and to identify 
the most important factors in the polymer’s performance in each test.  
In order to exhibit optimum function, the polymer system was designed to assess 
three functional criteria: binding to damaged tissue, suppression of protein adsorption, 
and reduction in cellular adhesion. In order to assess these functions, several techniques 
were employed. Quartz Crystal Microbalance with Dissipation (QCM-D) was used to 
study the kinetics and blockade of fibrinogen adsorption. The ability to retard the 
propagation of the FGM was studied using a turbidity assay to assess the kinetics of FGM 
formation from a fibrin-coated surface. The attachment of cells to polymer-treated fibrin 
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gels was investigated and quantified using a fluorescent DNA assay to mimic the action 
of macrophages during the rearrangement and strengthening phase of PSA formation.   
6.2. Materials and Methods 
6.2.1. Polymers 
 A total of 20 polymers, as synthesized in Chapter 4, were created for this 
analysis. As shown in Table 4-2, these polymer architectures included two levels each 
for the PEG chain length (MN = 300 and MN = 1,100) and the backbone chain length 
(approximately 24 and approximately 42 monomer units). In addition, the impact of 
peptide type (fibrin specific CREKA versus CAERK scramble) was investigated. The 
number of fibrin specific CREKA units per polymer molecule was varied from 2 – 5 
peptide units per molecule. Control polymers, consisting of functionalized PMAA units 
without PEG grafts were included in the analysis. Finally, free peptide (both CREKA and 
CAERK), as well as a commercially available phospholipid (egg phosphatidycholine, 
EPC) were used as controls. 
6.2.2. Solution Preparation 
Polystyrene (PS) solution was prepared by dissolving polystyrene (MN = 280,000, 
Fisher, 0.5 wt. %) in toluene (Fisher). Fibrinogen solutions (13.2 mg/ml, 0.50 mg/mL, 
and 0.10 mg/mL) were prepared in Tris Buffered Saline (TBS, Aldrich). Bovine Serum 
Albumin (BSA, Fisher, 1.0 mg/mL) solution was prepared in TBS. Thrombin solutions 
were prepared by diluting a stock thrombin solution (5 U/mL) to the desired 
concentrations in TBS (2.5 U/mL and 0.1 U/mL). All protein solutions were prepared 
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each day, prior to use. Polymer solutions were prepared by dissolving purified polymer in 
TBS to the desired final concentration and were stored at -20 oC prior to use. 
6.2.3. Measurement of Fibrinogen Adsorption to Fibrin Coated Quartz Crystal 
Our previously developed quartz crystal microbalance method was used to 
monitor the ability of targeted polymers to adsorb to fibrin coated samples and to block 
subsequent fibrinogen adsorption [5]. Shown schematically in Figure 6-1, this QCM 
analysis was carried out in a series of steps. First, polystyrene coated quartz crystals were 
prepared to promote protein adhesion. A layer of fibrinogen was allowed to adsorb to 
these crystals and was subsequently activated with thrombin to form a fibrin coated 
surface. After blocking nonspecific adsorption with BSA, the test material was 
introduced into the sample chamber. After a rinse step, a second fibrinogen adsorption 
step was carried out and the ability of the materials to suppress this fibrinogen binding 
was evaluated.   
6.2.3.1. Polystyrene Substrate Preparation 
Gold coated AT-cut quartz crystals with a fundamental frequency of 5 MHz 
obtained from Q-Sense were used as model substrates. These crystals were spin coated 
with polystyrene (PS) to create a uniform hydrophobic surface for fibrin adsorption using 
modifications of a previously described procedure [222]. Prior to coating with 
polystyrene, the crystals were cleaned by soaking in toluene for a minimum of two hours 
and dried in a stream of inert gas. They were subsequently spin coated with a PS solution 
at 2,500 RPM for 60 seconds using a Cee® 100 spin coater manufactured by Brewer 
Scientific and dried at 100 oC in a vacuum oven overnight. Using the parameters 
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described in Chapter 5, the thickness of the PS layer was measured using variable angle 
spectroscopic ellipsometry. Five samples were analyzed and the PS layer was determined 
to be 57.1 ± 8.4 nm. In order to ensure the repeatability of this surface preparation 
procedure, control QCM experiments with no barrier material were conducted 
periodically throughout the data acquisition and no notable differences were observed in 
the rate or level of fibrinogen deposition. 
6.2.3.2. QCM-D Analysis of Fibrinogen Deposition 
A schematic depiction of the QCM experiment is shown schematically in Figure 
6-1. The model substrate was first coated with a saturated layer of fibrinogen and 
activated with thrombin to create a surface bound fibrin layer. After blocking non-
specific protein adsorption with BSA, the surface was optionally treated with a solution 
of the protective polymer. A second fibrinogen adsorption step was then conducted. 
These experiments were conducted in the Q-Sense E4 at 37 oC with a flow rate of 50 
µL/min. Resonant frequency shift (• f) and energy dissipation (D) values were collected 
for the fundamental frequency and for odd harmonics (n = 1, 3, 5, 7, 9, 11, and 13) using 
the low noise setting for the duration of the experiment. 
After installing four crystals in parallel and verifying their quality (D < 30 ppm in 
air), TBS was flowed through the system until a stable baseline was obtained. An 
experiment was started with TBS flowing and, after 5 minutes, a solution of fibrinogen 
(0.1 mg/mL) was introduced into the system. After exposing the crystals to fibrinogen for 
15 minutes, the system was rinsed with TBS for 5 minutes. Thrombin (0.1 U/mL) was 
then flowed over the crystals for 10 minutes, followed by an additional 5 minute rinse 
with TBS. BSA (1.0 mg/mL) was allowed to interact with the surfaces for 10 minutes. 
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After rinsing again with buffer, a solution containing the analyte of interest (0.10 mg/mL 
in TBS) was introduced and allowed to flow through the system for 5 minutes. Unbound 
material was washed away with TBS for 5 minutes. A solution of fibrinogen (0.10 
mg/mL in TBS) was then introduced and flowed through the system for 25 minutes. 
Finally, the QCM was rinsed with of TBS for 20 minutes to facilitate the removal of 
unbound fibrinogen. As a control, the same procedure was followed without the addition 
of polymer solution or the subsequent buffer rinse. Each material was evaluated in a 
minimum of three experiments. 
Following each experiment, the QCM flow cells and all tubing were flushed with 
copious amounts of acidic ethanol (10% acetic acid in ethanol) followed by pure ethanol. 
The inability to obtain a stable baseline with consistent results without this cleaning 
process suggests the presence of residual protein or polymer in the system. The 
effectiveness of this cleaning procedure was verified by performing multiple experiments 
and confirming that the observed frequency and dissipation shifts were consistent. 
Finally, a stream of nitrogen was used to dry the QCM-D and the crystals were placed in 
a bath of toluene to remove the PS coating. 
6.2.4. Kinetic Determination of FGM Propagation using Fibrin Turbidity Assay 
Previous studies have demonstrated that surface adsorbed fibrin layers formed in 
this manner retain approximately five active thrombin molecules per fibrinogen molecule 
after rinsing with buffer solution [223]. These surfaces, then, can react with fibrinogen 
solutions to form a fibrin gel on the surface. A microplate assay was employed to monitor 
the reaction of surface bound fibrin with solution phase fibrinogen after treatment with 
various materials and to investigate the structure of the resulting fibrin gels [224-225].  
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6.2.4.1. Preparation of Fibrin Gel Substrate 
A Costar high binding 96-Well EIA/RIA plate was used to maximize the strength 
of interaction between the fibrin gel and the microplate. In order to create a stable gel on 
the surface, fibrinogen (50 µL, 2.0 mg/mL), thrombin (20 µL, 2.5 U/mL), and calcium 
chloride (10 µL, 100 mM) were added to each well. The resulting gel was allowed to cure 
for 5 hours at room temperature. Each well was then rinsed twice with 200 µL TBS, and 
care was taken to avoid removing the fibrin gel from the surface. A solution of each 
material under investigation (50 µL, 0.10 mg/mL in TBS, n = 4) was added to the wells.  
6.2.4.2. Assessment of Fibrin Gel Propagation 
After treating each gel with the material under investigation, 150 µL of fibrinogen 
(0.5 mg/mL in TBS) was added to each well. In order to observe the change in turbidity 
with time, a Cary Win-UV UV-visible spectrophotometer was used to monitor the UV 
absorbance at 350 nm for 90 minutes with an average time of 0.5 seconds using a two 
minute collection interval.  
6.2.5. Cellular Attachment to Fibrin Gels 
In order to test the anti-cellular adhesive properties of these materials, a 
complementary cell culture study was carried out using the mouse mesenchymal D1 cell 
line (ATCC CRL-12424) in 24-well tissue culture plates. This pluripotent cell line was 
selected due to its strong adherence to charged surfaces and wound healing components 
(e.g., collagen I and fibrin) [209-212].  
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6.2.5.1. Preparation of Fibrin Gels for Cell Culture Studies 
Stable fibrin gels were created in the well plates for use as a substrate to measure 
cellular attachment. Tris buffered saline was filtered through a 0.22 µm syringe filter and 
solutions (13.2 mg/mL fibrinogen, 5 U/mL thrombin, and 100 mM CaCl2) were prepared 
in a laminar flow hood to minimize microbial contamination. In each well, 152 µL of a 
fibrinogen solution was subsequently mixed with 40 µL CaCl2 solution and 8 µL 
thrombin solution to yield a solution that was 10 mg/mL fibrinogen, 20 mM CaCl2, and 
0.2 U/mL thrombin. This solution was allowed to gel at room temperature for 1 hour and 
was then allowed to mature overnight at 4oC.        
6.2.5.2. Cell Culture 
After rinsing the wells 3 times with sterile TBS, polymer solutions were added 
(200 µL, 0.10 mg/mL in sterile TBS) and incubated at 37 oC for 90 minutes. The polymer 
solutions were removed from the wells, and each well was rinsed 3 times with sterile 
TBS. Each well was then seeded with 250,000 cells in 500 µL Dulbecco’s Modified 
Eagle Medium (DMEM, HyClone Laboratories) containing 10% fetal bovine serum 
(GIBCO/Invitrogen) and incubated at 37 oC for two hours. Untreated tissue culture 
polystyrene (TCP) fibrin gels with no anti-adhesion barrier were employed as controls, 
and a minimum of 6 replicates were studied for each material. 
After incubation, unattached cells were removed from the wells by rinsing three 
times with sterile TBS. Representative images of the cells were obtained using an 
inverted phase contrast microscope. The cells remaining on the surface after rinsing were 
lysed by sonication in high salt solution (0.05 M NaH2PO4, 2 M NaCl, and 2 mM 
EDTA). DNA contents, measured using Hoechst 33258 stain, were used to quantify the 
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number of cells in each well [213-214].  In short, Hoechst 33258 (final concentration, 0.5 
µg/ml, Sigma) was allowed to react with lysates in the dark for 10 minutes, after which 
fluorescence was measured (• ex = 356 nm and • em = 458 nm).  An exponential calibration 
curve was prepared using samples with known DNA concentrations (0.16 – 5.0 µg/mL). 
After measuring the fluorescence of each well, this calibration was employed to 
determine concentration of DNA in each well. Since the duration of the experiment was 
not long enough for appreciable cell growth to occur, this value was used as a measure of 
the number of cells attached in each well.  
6.2.6. Statistical Analysis 
For comparisons, statistical relevance was determined by performing analysis of 
variance followed by a Sidak pair wise post-hoc analysis using Minitab 15. Each figure 
was analyzed separately. Differences at greater than 95% and 99% confidence are 
reported, with statistical significance being considered at the 95% level. Unless otherwise 
stated, all values are reported as mean ± standard error. 
In order to understand the impact of the molecular architecture on the various 
performance parameters evaluated, an additional statistical analysis was conducted. This 
modeling included the 16 block copolymers described in Table 6-1. The responses from 
the QCM analysis, turbidity assay, and cellular attachment study, were included in this 
analysis. For each response, ANOVA was carried out by fitting a general linear model 
using the variables of PEG chain length, number of PEG units, number of monomer units 
in the polymer backbone, peptide type, and number of peptide units per polymer 
molecule.  
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For each model, residual plots, including a normal probability plot, a frequency 
plot, and standardized residual plots were generated. These plots were used to verify the 
validity of the assumptions made in the general linear model. If the residuals are normally 
distributed, the normal probability plot is expected to show a linear trend with minor 
deviations in the tails. In addition, the frequency plot should by symmetrical with 
approximately 95% of the values within the range of ± 2 [226]. Finally, no apparent bias 
should be observed in the standardized residual plots [227-229]. In cases where apparent 
deviations from normality were observed, the analysis was repeated after removal of 
outliers to ensure that the trends predicted by model were unaffected. Main effects plots 
were then generated for each model in order to understand the impact of each factor. No 
outliers were removed from the analysis. 
6.3. Results 
The studies conducted provided data with a wide range of responses and, in most 
cases, low variability. If outliers were observed for a given model, they have been 
identified. The wealth of information that was obtained from these results provides the 
basis for a thorough understanding of the performance of the materials as a function of 
the structure of the polymer and the number and composition of the targeting moieties. In 
addition, the nature of any outliers provides insight into the limitation of the statistical 
model employed and can be interpreted to provide additional mechanistic information.   
6.3.1. QCM Analysis 
As can be seen in Figure 6-2, the energy dissipation observed with the fibrinogen 
coated samples (• D = 4 – 8 x 10-6) was much greater than what was seen in SAM 
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experiments (• D = 0.5 – 3 x 10-6, see Figure 5-7). As a result, the approximations 
employed in the Sauerbrey model are not valid, and the mass adsorbed on the surface 
could not be accurately determined. Instead, raw frequency response data was employed 
to extract pseudo-first order parameters for the maximum fibrinogen adsorption and the 
kinetic rate constant for the two fibrinogen adsorption events.  
Since the goal of these studies is to assess the ability of the materials to inhibit the 
adsorption of fibrinogen to a surface bound fibrin layer, two kinetic parameters are 
reported. First, the maximum fibrinogen adsorption observed in the second fibrinogen 
adsorption step was determined using a least squares analysis in Excel®. This value was 
then normalized to the first fibrinogen response and is reported as the ratio, �
Fg2Fg1�. In 
addition, the pseudo-first order kinetic half-life (t½,Fib) of the second fibrinogen 
adsorption step was determined using a least squares analysis in Excel®. 
The data in Figure 6-3 – Figure 6-5  present the frequency response for the 
materials studied. The mass of fibrinogen adsorbed in the second step was found to be 
dependent upon the nature of the barrier material employed. The ratio for the control 
samples with no polymer ( 
Fg2Fg1 = 0.54 ± 0.05), is shown on the figures as a horizontal line 
for reference. Statistical differences are indicated on the graphs. The P3 polymer 
conjugate with the high level of peptide conjugation (P3-H), which appears to be missing 
from the data, exhibited complete suppression of the second fibrinogen step in three 
experiments. As a result, all frequency responses for this material are reported as zero. 
Several other materials, including the peptide controls and the P4 conjugates and the 
PMAA conjugates PMAA-L and PMAA-S, exhibited significant levels of inhibition of 
the fibrinogen adsorption ratio. Several of the unconjugated polymers (PMAA, P2, and 
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P4) increased the second fibrinogen adsorption ratio dramatically (116%, 384%, and 
195%, respectively). The low level peptide conjugates of the long PEG chain polymers 
(P1-L and P3-L) failed to demonstrate suppression of fibrinogen adsorption.  
From the residual plots for fibrinogen adsorption, shown in Figure 6-6, it is seen 
that, with the exception of two notable outliers (P2 and P4), the normal probability plot is 
linear and that the residuals are normally distributed. The main effects plots, shown in 
Figure 6-7, indicate that the fibrinogen ratio decreases with increasing chain length and 
with increasing PEG chain length. The number of PEG chains per molecule does not 
show any clear trend. The two peptides reduce the value for the fibrinogen ratio, as does 
an increase in the number of peptides conjugated to the polymer. 
The results of the kinetic analysis for the second fibrinogen adsorption step are 
presented in Figure 6-8 – Figure 6-10. The half-life for the control samples without 
polymer adsorption (t½ = 530 ± 90 s) is shown on these graphs for reference. Since no 
fibrinogen was observed adsorbing to the surface for PS-3, no value is reported for this 
material. While there are differences among the materials tested, only PMAA (t½ = 1330 
± 160 s) and P2 (t½ = 2000 ± 280 s), demonstrated a significant difference in the kinetics 
of fibrinogen absorption from the control. 
The residual plots for the kinetics of fibrinogen adsorption, shown in Figure 6-11, 
confirm that, with the exception of 2 outliers (both P2), the normal probability plot is 
linear and the residuals are normally distributed. The main effects plots, shown in Figure 
6-12, indicate that the rate of fibrinogen adsorption is not a strong function of chain 
length or of the number of PEG chains. The kinetics slow with increasing PEG chain 
length The two peptides appear to reduce the rate of fibrinogen deposition, as does an 
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increase in the number of peptides conjugated to the polymer. Because of the relatively 
thick fibrin surface film and the large size of fibrinogen compared to BSA, the fibrinogen 
adsorption kinetics are slower that the BSA adsorption kinetics studied in Chapter 5 by 
an order of magnitude. 
6.3.2. Fibrin Turbidity Assay 
In order to assess the ability of the polymers to block the surface growth of the 
fibrin matrix, a kinetic assay was performed using the data obtained from 
spectrophotometry. After subtracting the initial absorbance values due to the preexisting 
fibrin layer in the microplate wells, the increase in turbidity could readily be observed. 
The rate of turbidity increase was approximated by fitting the initial data with a linear 
equation and determining the slope of the resulting line. As shown by the data in Figure 
6-13 – Figure 6-15, the value of this rate varies with the structure of the barrier material. 
The TBS control exhibited a value of 0.0039 ± 0.0007 min-1. There were no significant 
differences observed between the samples and the controls. Some statistically significant 
differences, however, were observed among the polymer samples. 
The residual plots for the kinetics of fibrinogen propagation, shown in Figure 
6-16, confirm that the normal probability plot is linear and the residuals are normally 
distributed. The main effects plots, Figure 6-17, indicate that the rate of fibrinogen 
propagation is not a strong function of chain length or number of PEG chains. The 
kinetics slow with increasing PEG chain length and with an increasing number of 
peptides conjugated to the structure. The CREKA peptide appears to reduce the rate of 
fibrinogen deposition, while the impact of the CAERK scramble is much less 
pronounced. 
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6.3.3. Cellular Attachment 
The results of the cellular attachment study, shown in Figure 6-18 – Figure 6-20, 
indicate that many of the materials significantly reduced the attachment of cells to the 
model fibrin surface. All of the PMAA polymers result in a significant reduction of 
cellular attachment, while the majority of the long PEG chain polymers show an effect. 
There were no significant differences observed with the short PEG chain polymers. As 
shown in Figure 6-21, images taken of the wells indicate that the cells were not 
uniformly distributed on the fibrin surface. This artifact of the cell loading procedure 
made accurate visual comparisons of the cells impossible. A comparison of the TCP 
versus the fibrin control wells, however, is very instructive. The fibrin control showed 
normalized cellular attachment of 1.00 ± 0.09, while the TCP control had cellular 
attachment values of 0.30 ± 0.09. This difference, also evident in the images in Figure 
6-21, results from the greatly enhanced surface area created by the three-dimensional 
network of the fibrin gel.   
The residual plots for the cellular attachment to the fibrin substrate are shown in 
Figure 6-22. With the exception of 1 outlier, the normal probability plot is linear and the 
residuals are normally distributed. The main effects plots, shown in Figure 6-23, suggest 
that the degree of cellular attachment is not function of the number of PEG units, PEG 
chain length, or the number of peptide units in the structure. The presence of peptide, 
both CREKA and CAERK, appears to promote cellular attachment. While no clear trend 
is evident in the performance as a function of polymer chain length, the longest polymer 
appears to provide enhanced resistance to cellular attachment.   
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6.4. Discussion 
The quartz crystal microbalance proved to be a very informative means to study 
the fibrinogen adsorption. Unlike the previous study (see Chapter 5), it was impossible 
to quantify the rate or degree of polymer adsorption to the model surfaces. The presence 
of the water-rich surface layer of fibrinogen resulted in high levels of energy dissipation 
and is probably responsible for this inability to discern the adsorption of these barrier 
materials. As has previously been described, the level of the second fibrinogen adsorption 
was normalized and reported as the ratio of the second fibrinogen adsorption step to the 
first (
Fg 2Fg 1). This technique was employed in order to eliminate the effect of the variability 
observed in the first fibrinogen adsorption step that resulted from a degraded frequency 
response as QCM crystals were repeatedly reused.  
Numerous properties of targeted block copolymers have been investigated to 
assess their ability to interrupt the physiological processes that lead to the formation of an 
extended gel matrix. Since this FGM formation is a prerequisite to the formation of post 
surgical adhesions, it is believed that the finding from these studies will be readily 
extended to understand the impact on material properties to the ability to reduce PSA 
formation. A summary of the effects of molecular architecture on these functional 
properties, summarized in Table 6-2, reveals several important relationships that provide 
insight into the mechanism of action. 
The ratio of fibrinogen adsorption in the QCM-D was studied to monitor the 
ability of these materials to reduce the affinity of surfaces for fibrinogen. It was 
anticipated that longer PEG chains, longer polymer chains, larger PEG chain density, and 
a larger density of targeted peptide units would provide increased protection against the 
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adsorption of fibrinogen to surface bound fibrin layers. This prediction was confirmed in 
most cases; in fact, the high molecular weight polymer with long PEG chains and a high 
level of CREKA (P3-H) resulted in the complete suppression of this second fibrin 
adsorption step. Compared to the rest of the polymer architectures, this structure appears 
to represent an optimum balance of surface affinity (due to the high peptide content) and 
protective ability (due to the long PEG chains). The difference observed between the 
short polymer chain and long polymer chain is also notable. The shorter polymer chains 
are much less effective at inhibiting fibrinogen adsorption, potentially as a result of the 
action of the PEG groups on the peptide units. The long PEG chains can articulate and 
form a hydration shell of approximately the same dimensions as the shorter polymer and 
shield the attached peptide units from interacting strongly with the fibrin surface. The 
longer polymer chains extend past this shell and present readily available peptide units to 
the active surface.  
The rate of fibrinogen adsorption, while similar for most of the materials, appears 
to be slowed for the PMAA and P2 polymers. It is possible that this apparent reduction in 
rate is an artifact of mass transfer limitations related to the very high level of fibrinogen 
adsorbed for these materials.   
Most of the polymers appear to slow the kinetics of fibrin propagation. 
Unfortunately, due to the wide degree of variability in the data, very few statistically 
significant differences were observed in this rate. The phospholipid (EPC), on the other 
hand, appears to enhance the rate of fibrin propagation. This probably results from the 
simultaneous growth of phospholipid lamella within the fibrin gel matrix structure. Since 
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both of these structures can scatter light, such a mechanism would lead to the more rapid 
turbidity increase. 
Cellular attachment studies resulted in several interesting observations. As a result 
of their highly negative charge, the PMAA polymers were surprisingly effective at 
reducing the observed cellular attachment. While few statistically significant differences 
were observed in the level of cellular attachment, all of the materials appear to reduce this 
response compared to the untreated fibrin control. It can be deduced, then, that all of the 
materials adsorb to the fibrin gel surface and can reduce cellular attachment through 
either steric hindrance or charge based repulsion.    
Using statistical analysis, it is possible to develop a better understanding of the 
relationships between the molecular structure and the performance in these experiments. 
The trends seen in the factor plots can be used to inform decisions about the development 
of subsequent materials and can serve as the basis for additional mechanistic 
understanding. Finally, these statistical techniques allow for the identification of potential 
outliers that may lead to additional understanding of the mechanism or experimental 
design.  
The results obtained from the QCM experiments reveal several trends in the 
ability of these materials to suppress this fibrinogen adsorption. The trends are 
summarized in Table 6-2. Based on the summary data, it is possible to identify several 
attributes of the polymer architecture that are important for the attenuation of post 
surgical adhesion formation. The length of the PEG chains appears to be an important 
determinants of performance for the materials. Neither the number of PEG chains in each 
polymer molecule nor the polymer chain length appear to be major factors in assessing 
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the performance. The largest impact on performance appears to arise from the peptide 
units. While the number of peptide units appears to be very important, the most 
unexpected results were observed when assessing the impact of the peptide type on 
material performance.  
For many of the experiments, the number of peptide units conjugated to the 
polymer is a strong predictor of the material’s performance. In most instances, however, 
the impact of the nature of the peptide was much less pronounces. This result was 
particularly surprising since CREKA has been shown to be an excellent targeting moiety 
for protein clots [171-173, 177]. CAERK, on the other hand, was not anticipated to show 
a high affinity for fibrinogen. While polymers conjugated with CREKA and CAERK 
both inhibit the degree and rate of subsequent fibrinogen adsorption and reduce the level 
of cellular attachment to model surfaces, the CREKA-based materials are much more 
effective at reducing the propagation of fibrin from a surface. These effects may be 
attributable to differences in the precise nature of the binding epitopes for the two peptide 
units. Both peptides exhibit an affinity for fibrin and can direct polymeric materials to 
associate with the fibrin-coated surfaces form barriers to subsequent protein adsorption 
and cellular attachment. The relative ineffectiveness of the CAERK materials at reducing 
fibrin polymerization from surfaces suggests that this peptide unit competes less 
effectively for the binding sites where subsequent fibrinogen polymerization occurs.   
The effect of PEG chain length in each of the experiments indicates that longer 
polyethylene glycol units are more likely to result in a material likely to interrupt the PSA 
formation process. Longer PEG chains have been shown to result in increasing resistance 
to protein adsorption, so this result agrees with previously reported observations. The 
 116 
 
 
relationship between an increase in the PEG length and a decrease in the degree and 
kinetics of fibrinogen adsorption is likely a result of the increasing thickness of the 
hydrated PEG layer with longer PEG chains. As this layer becomes thicker, not only does 
the affinity of fibrinogen for the surface layer decrease, but mass transport limitations 
through this hydrated layer suppress the rate of surface adsorption.  
A similar mechanism also explains the ability of the long PEG chain materials to 
protect surfaces from cellular attachment and to retard the propagation of the fibrin gel 
matrix. The decrease in cellular attachment results from the inability of proteins to attach 
to thick, hydrated PEG layers. The decrease in the rate of fibrin propagation may arise 
from an increase in mass transport limitations due to hydrated PEG layer. In order for the 
solution phase fibrinogen to polymerize and form a fibrin gel, it must be activated with 
the surface bound thrombin. If this thrombin is coated with the PEG containing polymer, 
the fibrinogen must diffuse through this layer to the active site.  Longer PEG chains, then, 
can inhibit the rate of fibrin gel propagation from the model surface more effectively than 
shorter PEG chains. 
Surprisingly, the number of polyethylene glycol chains per polymer molecule 
does not appear to impact the fibrinogen blocking ability of the materials. Although the 
level of polymer adsorption could not be directly observed in these experiments, this lack 
of dependence on the concentration of PEG chains may result from the formation of a 
surface layer with complete PEG coverage. Once this level of surface saturation is 
achieved, further adsorption of polymers to the surface is unlikely. This knowledge may 
provide a means of tailoring the durability of the surface films formed by these materials. 
Since the desorption of polymers from surfaces should be first order with respect to the 
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number of polymer chains on a surface, having a larger number of chains on the surface 
may lead to longer lasting surface protection. Since the number of surface bound polymer 
molecules appears to be indirectly related to the number of PEG chains per molecule, it 
may be possible to create longer lasting surface films with similar performance properties 
by forming polymers with a low number of PEG chains per molecule. 
6.5. Conclusion 
The techniques employed in this study allowed for a thorough investigation of the 
relationship between the structure and function for a series of targeted block copolymers. 
By systematically varying multiple aspects of the molecular architecture and employing 
statistical analysis to study these structure-function relationships, the complex nature of 
these materials to inhibit FMG propagation were successfully probed. As was anticipated, 
the function of these materials was highly dependent on the molecular architecture of the 
polymer. 
As expected, longer PEG chains tend to inhibit all of the potential pathways of 
PSA that were modeled. While the number of PEG chains in each polymer molecule did 
not appreciably affect the performance, the impact of the number of peptide units was 
dramatic. In addition, the subtle differences in the performance of the two peptides 
support the hypothesis that targeting can be used to direct the performance of materials to 
interrupt the formation of the fibrin gel matrix and prevent the formation of post surgical 
adhesions. Although the CREKA functionalized polymers functioned very well in all 
tests, the CAERK scramble signaled similar efficacy in many cases. This observation 
suggests that CAERK may also be an effective targeting unit for the fibrin molecule. The 
relationships between the molecular architecture and performance provide valuable 
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insight and form a knowledge base that can be used to inform future investigations of 
biomaterials for PSA prevention.     
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Figure 6-1  Schematic representation of proposed fibrin blockade mechanism in QCM 
analysis. 
 A surface-bound fibrin film is first generated by adsorption to the 
polystyrene surface and activation with fibrinogen. After blocking 
uncoated surface sites with BSA, a second fibrinogen adsorption step is 
carried out, and a large amount of fibrinogen is observed adsorbing to the 
surface. If the initial fibrin layer is treated with a polymeric adhesive 
barrier material, the amount of fibrinogen adsorbed in this second step can 
be greatly reduced. 
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Figure 6-2  Representative QCM sensorgram of fibrinogen suppression study. 
 After establishing a baseline in tris buffered saline (TBS), fibrinogen, 
thrombin, bovine serum albumin (BSA), polymer, and fibrinogen 
solutions were introduced into the system sequentially. As indicated by the 
shaded regions, a TBS wash was employed between solution 
introductions. The frequency shift (∆f, blue) and energy dissipation 
change (∆D, red) were monitored continuously throughout the experiment.  
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Figure 6-3  Fibrinogen adsorption ratio for controls and PMAA polymers. 
Values (M ± SE) represent the mass ratio seen in the final and initial 
fibrinogen adsorption steps. The horizontal bar represents the ratio 
observed for the control samples with no polymer treatment. Statistically 
significant differences are reported: 99% compared to no polymer (b), 
99% compared to PMAA (d), 95% compared to PMAA-H (e), 99% 
compared to PMAA-H (f), 95% compared to EPC (g), and 99% compared 
to EPC (h). 
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Figure 6-4  Fibrinogen adsorption ratio for long (MN = 1,100) PEG chain polymers. 
Values (M ± SE) represent the mass ratio seen in the final and initial 
fibrinogen adsorption steps. The horizontal bar represents the ratio 
observed for the control samples with no polymer treatment. No 
absorption was observed for P3-H in the second adsorption step. 
Statistically significant differences are reported: 99% compared to no 
polymer (b), 95% compared to P3-H (i), and 99% compared to P3-H (j). 
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Figure 6-5  Fibrinogen adsorption ratio for short PEG (MN = 300) chain polymers. 
Values (M ± SE) represent the mass ratio seen in the final and initial 
fibrinogen adsorption steps. The horizontal bar represents the ratio 
observed for the control samples with no polymer treatment. Statistically 
significant differences are reported: 99% compared to no polymer (b), 
95% compared to P2 (k), 99% compared to P2 (l), and 99% compared to 
P4 (n). 
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Figure 6-6  Residual plots for fibrinogen adsorption ratio. 
 The validity of the general linear model used for the ANOVA for the 
fibrinogen adsorption ratio is confirmed by the residual plots. The linearity 
of the normal probability plot and random distribution observed in the 
standardized residual plots indicate a lack of bias in the model fit. The 
histogram of standardized residuals indicates a normal distribution of 
residuals. In addition, the vast majority of the residuals are within the 
expected range of ± 2 standard deviations. The two outliers with 
standardized residuals above 3 result from the wide variability in the data 
for the short PEG chain polymers without peptide conjugation (P2 and 
P4).  
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Figure 6-7  Main effects plot for fibrinogen adsorption ratio. 
The main effects plots for the ratio of fibrinogen adsorption provide 
insight into the importance of the various aspects of polymer architecture 
that were investigated. As indicated by the strong dependence of the 
response to the number of peptide units (Peptide No) and the peptide type, 
these two factors have the most influence on the performance in this 
experiment. The existence of peptide units in the polymer is of critical 
importance, while the impact of peptide type is unclear. More peptide 
units lead to a decrease in the observed fibrinogen ratio. Increases PEG 
length decrease the fibrinogen adsorption ratio, while no statistically 
significant trend is evident with changes in the number of PEG groups in 
each polymer molecule or in the overall chain length. 
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Figure 6-8  Fibrinogen adsorption kinetics for controls and PMAA polymers. 
Values (M ± SE) represent the kinetic half-life seen in the second 
fibrinogen adsorption step. The horizontal bar represents the half-life 
observed for the control samples with no polymer treatment. Statistically 
significant differences are reported: 99% compared to no polymer (b), 
99% compared to PMAA (d), 99% compared to PMAA-H (f), and 95% 
compared to CAERK (o). 
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Figure 6-9 Fibrinogen adsorption kinetics for long PEG chain (MN = 1,100) 
polymers. 
Values (M ± SE) represent the kinetic half-life seen in the second 
fibrinogen adsorption step. The horizontal bar represents the half-life 
observed for the control samples with no polymer treatment.  No 
statistically significant differences were observed. 
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Figure 6-10  Fibrinogen adsorption kinetics for short PEG chain (MN = 300) polymers. 
Values (M ± SE) represent the kinetic half-life seen in the second 
fibrinogen adsorption step. The horizontal bar represents the half-life 
observed for the control samples with no polymer treatment. Statistically 
significant differences are reported: 99% compared to no polymer (b), and 
99% compared to P2 (l). 
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Figure 6-11  Residual plots for the kinetic half-life of the second fibrinogen adsorption 
step in QCM experiments. 
 The validity of the general linear model used for the ANOVA for the half-
life of the second fibrinogen adsorption step is supported by the residual 
plots. There are, however, two apparent outliers, both for the short PEG 
chain polymer with no peptide (P2). With the exception of these outliers, 
the linearity of the normal probability plot and random distribution 
observed in the standardized residual plots indicate a lack of bias in the 
model fit. The histogram of standardized residuals suggests a normal 
distribution of residuals. Excepting the two outliers, all of the residuals are 
within the expected range of ± 2 standard deviations.  
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Figure 6-12  Main effects plots for the kinetic half-life of second fibrinogen adsorption 
step. 
The main effects plots for the half-life of the second fibrinogen adsorption 
step provide insight into the importance of the various aspects of polymer 
architecture that were investigated. As indicated by the strong dependence 
of the response to the peptide type this factor has the largest influence on 
the performance in this experiment. The presence of peptide units in the 
polymer is of critical importance, while the impact of peptide type is 
unclear. Increases in PEG length and in the number of PEG units appear to 
decrease rate of fibrinogen deposition. No statistically significant trend is 
evident with changes in the overall chain length of the polymer or with the 
number of peptide units. 
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Figure 6-13  Kinetic analysis of fibrin gel propagation from fibrin surface for controls 
and PMAA polymers. 
Values (M ± SE) represent the initial rate of turbidity increase observed 
during fibrin propagation. The horizontal bar represents the half-life 
observed for the control samples with no polymer treatment. Statistically 
significant differences are reported: 99% compared to PMAA (d), and 
95% compared to EPC (g). 
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Figure 6-14  Kinetic analysis of fibrin gel propagation from fibrin surface for long PEG 
chain (MN = 1,100) polymers. 
Values (M ± SE) represent the initial rate of turbidity increase observed 
during fibrin propagation. The horizontal bar represents the half-life 
observed for the control samples with no polymer treatment. Statistically 
significant differences are reported: 95% compared to P1 (q). 
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Figure 6-15  Kinetic analysis of fibrin gel propagation from fibrin surface for short 
PEG chain (MN = 300) polymers. 
Values (M ± SE) represent the initial rate of turbidity increase observed 
during fibrin propagation. The horizontal bar represents the half-life 
observed for the control samples with no polymer treatment. No 
statistically significant differences were observed. 
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Figure 6-16  Residual plots for kinetic analysis of fibrin gel propagation from fibrin 
surface. 
The validity of the general linear model used for the ANOVA for the 
kinetic analysis of fibrin gel propagation is supported by the residual plots. 
There is, however, one apparent outlier, that results from the short PEG 
chain polymer with no peptide (P2). With the exception of this outlier, the 
linearity of the normal probability plot and random distribution observed 
in the standardized residual plots indicate a lack of bias in the model fit. 
The histogram of standardized residuals suggests a normal distribution of 
residuals. Excepting the outlier, all of the residuals are within the expected 
range of ± 2 standard deviations. 
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Figure 6-17  Main effects plots for the kinetics of fibrin propagation. 
The main effects plots for the kinetics of fibrin propagation provide 
insight into the importance of the various aspects of polymer architecture 
that were investigated. As indicated by the strong dependence of the 
response to the number of peptide units (Peptide No) and the peptide type, 
these two factors have the largest influence on the performance in this 
experiment. The type of peptide units in the polymer is of critical 
importance. No statistically significant trends were observed with changes 
in the number of peptide units, PEG chain length, or overall chain length. 
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Figure 6-18  Normalized cellular attachment data for controls and PMAA polymers. 
Values (M ± SE) represent the degree of cellular attachment, based on 
DNA assay, normalized to fibrin controls. Statistically significant 
differences are reported: 95% compared to no polymer (a), and 99% 
compared to no polymer (b). 
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Figure 6-19 Normalized cellular attachment data for long PEG chain (MN = 1,100) 
polymers. 
Values (M ± SE) represent the degree of cellular attachment, based on 
DNA assay, normalized to fibrin controls. Statistically significant 
differences are reported: 95% compared to no polymer (a), and 99% 
compared to no polymer (b). 
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Figure 6-20  Normalized cellular attachment data for short PEG chain (MN = 300) 
polymers. 
Values (M ± SE) represent the degree of cellular attachment, based on 
DNA assay, normalized to fibrin controls. No statistically significant 
differences were observed. 
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Figure 6-21  Images of cells attached to fibrin gel after treatment with barrier material. 
 These images (Fibrin, TCP, PMAA-S, P1-L, and P1-S, clockwise from top 
left) are representative of the cells after incubation. The heterogeneous 
distribution of cells in the wells made accurate visual assessment of the 
cellular density impossible. 
 
 
 
 
 
 
Copyright © John M. Medley 2010 
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Figure 6-22  Residual plots for attachment of cells to fibrin substrate. 
The validity of the general linear model used for the ANOVA for the 
kinetic analysis of fibrin gel propagation is supported by the residual plots. 
There are, however, three apparent outliers. These outliers result from P2-
H, P2-S, and P3-L. With the exception of these outliers, the linearity of the 
normal probability plot and random distribution observed in the 
standardized residual plots indicate a lack of bias in the model fit. The 
histogram of standardized residuals suggests a normal distribution of 
residuals. Excepting the outliers, all of the residuals are within the 
expected range of ± 2 standard deviations. The outliers potentially result 
from the non-linear nature of the fluorescence assay employed for the 
quantification of cellular attachment, where small experimental variation 
can result in large variation in the results. 
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Figure 6-23  Main effects plots for attachment of cells to fibrin substrate. 
The main effects plots for the attachment of cells to fibrin substrate 
provide insight into the importance of the various aspects of polymer 
architecture that were investigated. As indicated by the strong dependence 
of the response to the presence of peptide, this factor has the largest 
influence on the performance in this experiment. No trend is observed for 
the response with changes in polymer chain length; however, the longest 
chain length material showed a dramatic decrease in the level of cellular 
attachment. No statistically significant trend was observed with changes in 
PEG chain length, number of PEG chains, or number of peptide units. 
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Table 6-1  Polymers Included in General Linear Model for Targeted Polymer 
Analysis 
 
Polymer 
Code 
Functional 
Group 
Number of 
Functional 
Groups 
Chain 
Length 
Number 
of MA 
Units 
Number 
of PEG 
Units 
MA/PEG 
Ratio 
PEG 
Chain 
Length 
Molecular 
Weight 
P1 - - 18.4 15.9 2.5 6.5 1,100 4,300 
P1-L CREKA 2.3 18.4 15.9 2.5 6.5 1,100 9,300 
P1-H CREKA 6.7 18.4 15.9 2.5 6.5 1,100 14,400 
P1-S CAERK 2.4 18.4 15.9 2.5 6.5 1,100 9,300 
P2 - - 18.2 16.0 2.2 7.3 300 2,200 
P2-L CREKA 2.4 18.2 16.0 2.2 7.3 300 7,300 
P2-H CREKA 7.4 18.2 16.0 2.2 7.3 300 12,800 
P2-S CAERK 2.4 18.2 16.0 2.2 7.3 300 7,300 
P3 - - 30.9 26.7 4.2 6.4 1,100 7,300 
P3-L1 CREKA 2.2 30.9 26.7 4.2 6.4 1,100 14,800 
P3-H CREKA 6.2 30.9 26.7 4.2 6.4 1,100 21,000 
P3-S CAERK 2.2 30.9 26.7 4.2 6.4 1,100 14,800 
P4 - - 22.1 17.5 4.6 3.8 300 3,300 
P4-L CREKA 2.3 22.1 17.5 4.6 3.8 300 8,700 
P4-H CREKA 7.1 22.1 17.5 4.6 3.8 300 14,200 
P4-S CAERK 2.3 22.1 17.5 4.6 3.8 300 8,600 
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Table 6-2 Effects of Variation in Molecular Architecture on Material Performance 
 
  Response 
  
Fibrinogen 
Adsorption Ratio 
�
𝐅𝐅𝐠𝐠𝟐𝟐
𝐅𝐅𝐠𝐠𝟏𝟏
� 
Fibrinogen 
Deposition Half-Life 
Initial Rate of 
Fibrin Gel 
Propagation 
Cellular 
Attachment 
V
ar
ia
bl
e 
Chain 
Length    ↓* 
PEG Chain 
Length ↓ ↓   
Number of 
PEG Units  ↓   
Number of 
Peptide 
Units  
↓  ↓  
Peptide 
Type NS NS S NS 
 
Summary of statistically significant (p < 0.05) effects of polymer architecture on 
performance in in vitro and ex vivo tests. The “↓” symbol indicates a decrease in the 
response when the variable value is increased. Designations of “S” and “NS” indicate 
effects that are specific (S) or not specific (NS) to the type of peptide unit conjugated to 
the polymer. The “*” symbol indicates that the response only shows negative correlation 
with the variable for the longest polymer chains. 
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CHAPTER 7. INVESTIGATION OF INTERACTION BETWEEN CREKA AND 
FIBRINOGEN 
 
7.1. Introduction 
As has been demonstrated in the literature, the pentapeptide CREKA has 
successfully been used to target nanoparticles to tumor sites based on the high levels of 
fibrin present due to the well characterized leaky vasculature [168-173]. In addition, the 
molecular configuration of this material has been characterized under a variety of 
conditions [175-177]. The work described in Chapter 6 demonstrates that CREKA can 
also be incorporated into polymers and used to interrupt the series of events that leads to 
an extended fibrin gel matrix, promoting post surgical adhesion formation. To date, 
however, no analysis of the interaction of this peptide with fibrin, or its precursor, 
fibrinogen, has been reported.  
Two complementary approaches were employed to begin the investigation of this 
important interaction. First, the structure of fibrin gels grown from surfaces treated with a 
series of polymeric materials was analyzed using a turbidity assay. The powerful optical 
technique, circular dichroism (CD), was employed to probe the interaction of this peptide 
with fibrinogen in the solution phase. While a much more detailed investigation of this 
interaction is warranted, these two studies represent a critical first step in developing an 
understanding of the nature of these interactions. 
7.2. Materials and Methods 
For the structural analysis if fibrin, all of the materials listed in Table 4-2 were 
employed. Circular dichroism was carried out with the free targeting peptide (CREKA) 
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and the polymer conjugate deemed to have the best overall performance from previous 
experiments (P3-H). All materials were prepared as previously described. 
7.2.1. Analysis of Fibrin Structure using UV-Visible Turbidity Assay 
In order to investigate the structure of fibrin gels grown from the surface of 
existing fibrin substrates under a variety of conditions, a microplate based turbidity 
analysis was performed [224-225]. 
7.2.1.1. Preparation of Fibrin Gel Substrate 
A Costar high binding 96-Well EIA/RIA plate was used to maximize the strength 
of interaction between the fibrin gel and the microplate. In order to create a stable gel on 
the surface, fibrinogen (50 µL, 2.0 mg/mL), thrombin (20 µL, 2.5 U/mL), and calcium 
chloride (10 µL, 100 mM) were added to each well. The resulting gel was allowed to cure 
for 5 hours at room temperature. Each well was then rinsed twice with 200 µL TBS, and 
care was taken to avoid removing the fibrin gel from the surface. A solution of each 
material under investigation (50 µL, 0.10 mg/mL in TBS, n = 4) was added to the wells. 
7.2.1.2. Assessment of Fibrin Gel Structure 
After treating each gel with the material under investigation, 150 µL of fibrinogen 
(0.5 mg/mL in TBS) was added to each well. A partial UV-visible spectrum (350 – 500 
nm) was collected for each well using the CaryWin UV UV-visible spectrophotometer. 
After 90 minutes, a second UV-visible spectrum was collected. The turbidity of the 
additional fibrin gel formed during the intervening 90 minutes was determined by 
subtracting the initial reading from the final reading at each wavelength. 
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Previously published studies have shown that it is possible to relate the turbidity 
of the resulting gel to the structure of its composite fibers [223, 230-233].  Turbidity (•) 
can be calculated from the measured absorbance (Abs) value and the path length (b):  
 
τ = ln (10)∗Absb     (7-1). 
 
As shown in Appendix A, this value can be related to the 
masslength  ratio (µ) of the fibrin 
fibrils by Equation (7-2): 
 
τ = 6.52×10−27
λ3 ∙ μ    (7-2). 
 
As indicated by this expression, a plot of • versus �
6.52×10−27
λ3 � should yield a straight line 
with a slope of µ. Assuming an average well diameter of 0.661 mm, a 150 µL gel results 
in a path length of 0.437 cm. Equation (7-2) can be employed, and a plot of • versus 
6.52×10−27
𝜆𝜆3  will yield a straight line with a slope equal to the ratio of mass to length ratio of 
the fibrin fibrils (µ) in �
Dacm� to relate the turbidity of the gel to its structure.   
7.2.2. Circular Dichroism of Fibrinogen with Free Peptide and with Targeted 
Polymeric Adhesion Barrier 
Circular dichroism (CD) is a powerful optical technique often employed to 
investigate the structure of proteins in solution and to probe the interaction of materials 
with these proteins. Briefly, a sample of the material of interest is dissolved in a solvent 
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and irradiated alternately with circularly polarized light with opposite polarities. Since 
proteins fold into chiral structures, they interact differently with these two polarized 
beams. The absorbed light is measured as a function of wavelength for each beam, and 
the difference between these absorption values is used to study the structure of the 
analyte. Numerous articles and books have been written describing the underlying 
physics of the technique [234-237]. Other manuscripts offer guidance on the 
experimental and analytical aspects of CD measurement [238]. Because of the nature of 
the technique, it is necessary that the protein of interest be dissolved in a UV transparent 
solvent. As a result, direct investigation of the insoluble fibrin molecule is impossible; 
rather, it is customary to investigate interactions between ligands and fibrinogen and then 
to apply these results to fibrin [239-241]. In this work, we employ this technique to study 
the interaction between targeting peptides and solution phase fibrinogen. 
7.2.2.1. Preparation of Solutions for CD Measurements 
Prior to preparing solutions, PBS was filtered with a 0.22 µm syringe filter. 
Solutions of fibrinogen (0.1 to 200 µg/mL), CREKA (100 µg/mL), and P3-H (100 
µg/mL) were prepared in this PBS buffer solution. These solutions were combined in the 
appropriate ratios and diluted with PBS to prepare the samples shown in Table 7-1. All 
samples were prepared fresh on the day of the experiment to minimize degradation of the 
proteins in solution. 
7.2.2.2. Circular Dichroism Measurement 
All CD measurements were performed at 37 oC using the Jasco J-810 
Spectropolarimeter controlled by the Jasco Spectral Measurement software. Spectra were 
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collected from 320 to 200 nm. Each measurement is the average of four acquisitions 
collected in a 1.0 mm quartz cuvette, and each sample was measured three times. In order 
to avoid contamination between samples, the cuvette was cleaned with 1M nitric acid, 
rinsed with copious amounts of DI water and ethanol, and dried with acetone between 
samples. Analysis of blank PBS samples confirmed that this cleaning procedure removed 
all traced of the sample from the cuvette. 
7.2.2.3. CD Data Analysis 
In order to estimate the content of • -helical and • -sheet secondary structure in the 
fibrinogen, each spectrum was analyzed using the K2D2 neural network deconvolution 
algorithm [242-244]. This algorithm, accessible via an online interface, uses a neural 
network to assess the structure of proteins in aqueous solution. By comparing the 
observed CD spectrum with a database of 43 proteins with known structures, the K2D2 
network can effectively estimate the • -helical and • -sheet content in the sample. 
7.3. Results 
7.3.2. Fibrin Structure 
As previously described, the structure of the fibrils within a fibrin gel can be 
probed by analyzing the turbidity of the gel as a function of wavelength. As shown in 
Figure 7-1, a plot of • versus �
6.52×10−27
𝜆𝜆3 �, yields a straight line, in good agreement with 
theory. Using a linear least squares analysis in Excel, data for each well was analyzed. 
The results of this analysis, shown in Figure 7-2 – Figure 7-4, summarize these results 
for the materials tested. The control, with no polymer addition, yields a value of  
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2.56 × 1012  ± 1.7 × 1011  Dacm  and is shown on the figures as a horizontal line for 
reference. Only EPC exhibited a statistical difference from the TBS control.  
The residual plots for µ are shown in Figure 7-5. With the possible exception of 1 
outlier, the normal probability plot is linear and the residuals are normally distributed. 
The main effects plots, shown in Figure 7-6, indicate mass/length ratio is not affected by 
the polymer chain length, the number of PEG chains, or the number of peptide units. The 
value of µ decreases with increasing PEG chain length . No clear difference is observed 
as a function of peptide type.  
7.3.3. CD Analysis 
Representative CD spectra for the samples tested are shown in Figure 7-7. These 
spectra indicate a change in secondary protein structure with the addition of either 
CREKA or polymer. The intensity of the peak at 210 nm decreases with increasing 
CREKA concentration; the effect of the polymer (100 µg/mL) is approximately 
equivalent to the effect of 0.2 µg/mL of CREKA.  
Circular dichroism measurements of solution phase fibrinogen in the absence of 
targeting peptides indicate 32.5 ± 7.0 percent • -helical content and 20.4 ± 5.8 percent • -
sheet content. These results are in good agreement with previously published structural 
data (35 – 42 percent • -helix, 20 – 25 percent • -sheet) and validate the accuracy of the 
subsequent CD measurements [245-246]. As shown in Table 7-1, the addition of 
CREKA or CAERK to the fibrinogen solution does not result in a significant change in 
the • -helical content. The addition of CREKA at 0.20 and 1.0 µg/mL causes a decrease in 
the • -sheet content from 20.4 ± 5.8 percent to approximately 12.4 ± 1.2 percent and 12.5 
± 1.5 percent, respectively. A dose dependant decrease in • -sheet content was observed 
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with the scramble peptide. The addition of 0.20 µg/mL CAERK results in a • -sheet 
content of 16.0 ± 4.5 percent, while the sample with 1.0 µg/mL CAERK exhibited 10.2 ± 
0.2 percent • -sheet content. The addition of 1.0 µg/mL P3-H to the fibrinogen solution 
caused no decrease in • -helical content but did result in a decrease in • -sheet content to 
12.6 percent. 
7.4. Discussion 
As indicated by the data in this section, the materials tested in these studies had a 
significant effect on the structure of fibrin gels propagated from an existing fibrin surface. 
Although the individual comparisons reported in Figure 7-2 – Figure 7-4 fail to reveal a 
strong significant difference among the samples, ANOVA analysis conducted on the 
entire data set of polymer samples did reveal several important, statistically significant, 
trends.  
The effect of PEG chain length, indicating that longer PEG chains result in a 
decrease in the mass/length ratio for the fibrin fibrils, suggests that longer PEG chains are 
effective at inhibiting the deposition of fibrinogen to growing fibrin fibrils. As has been 
discussed in Chapter 6, this result is in good agreement with previously published 
studies, where the length of PEG chain is an important factor in the ability to suppress 
protein adsorption. Surprisingly, the number of PEG chains does not appear to impact the 
structure of the growing fibrin fibrils. This indicates that the steric effect of PEG chains 
on adjacent monomer units in the polymer fails to result in enhanced protection against 
protein deposition. It is possible that, in the environment tested, all of the PEG chains 
form a fully hydrated hydrophilic core. While it was impossible to determine the number 
of polymer chains adsorbed to the growing fibrin fibril, it is likely that a larger number of 
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low PEG number polymer chains are able to adhere to the surface. As a result, the total 
number of PEG chains on the surface may be equivalent despite the difference in 
molecular architecture. 
The somewhat surprising observation that polymer chain length does not affect 
the resulting fibrin structure may also be explained if it is assumed that the surface of the 
fibrin fibrils is saturated with polymer. Although the longer polymer chains occupy a 
larger surface area, the presence of additional polymer chains results in an equivalent 
effect on the polymerized protein structure. 
Although the trend in protein structure that results from changing the peptide is 
ambiguous, it does appear that the presence of either CREKA or CAERK in the polymer 
structure results in an increase in the specific mass of the fibrils. This is confirmed by the 
clear trend observed that increasing the level of peptide conjugation increases the 
measured value of µ. Two mechanisms may be responsible for this trend. If the presence 
of the peptide simply increases the affinity for the polymers to the fibrin fibril surface, it 
is conceivable that the observed increase simply results from the accumulation of 
polymer around the fibrin core. Another potential explanation for this observation is that 
the peptides on the polymer chain enhance the deposition of fibrin around these growing 
fibrils by increasing the interacting with the solution phase protein and the growing fibril. 
Without additional structural information about the structure of the fibrin generated in 
these experiments, it is impossible to distinguish between these two potentialities; 
however, since is appears likely that the surfaces are completely saturated with polymer, 
the second explanation appears to be more likely.  
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The observations made with circular dichroism can be used to begin to explain the 
interaction of CREKA with fibrin and its precursor, fibrinogen. The fibrinogen solution 
employed was prepared at a concentration of 100 µg/mL, or 0.29 µM. The peptide was 
employed at concentrations of 0.33 and 1.7 µM. Since CD of the free peptide did not 
reveal any secondary structure, all structural changes in the protein/peptide mixture were 
attributed to alterations in the conformation of fibrinogen.  
These preliminary circular dichroism measurements revealed what appears to be a 
strong interaction between the peptide ligands and the fibrinogen molecule. The native 
protein structure, which is in good agreement with previously published studies, showed 
a large degree of change when incubated with the targeting peptides [245-249]. At either 
a low (1.1:1) or high (5.6:1) peptide/protein ratio, the CREKA causes a similar 
conformational change. The scramble, on the other hand, shows less change at the lower 
concentration. This result indicates that, while CAERK binds to fibrinogen, it does so 
with a much lower affinity than CREKA. In addition, since the CD data shows no change 
in the • -helical content in the protein, it can be concluded that the binding site(s) for the 
two peptides all reside in the • -sheet domains of the protein. The fact that no additional 
conformational change is observed with greater than a 1.1:1 ratio of peptide to protein 
suggests that each fibrinogen molecule contains only one peptide binding site. Although 
these observations have a high degree of variability and do not provide sufficient detail to 
discern the precise nature of the interaction between CREKA and fibrinogen, the large 
conformational change suggests that CREKA interacts strongly with solution phase 
fibrinogen.  
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7.5. Conclusion 
The materials tested for use as prophylactic treatments for post surgical adhesion 
prevention demonstrate the ability to bind to growing fibrin fibrils and to affect the 
structure of the resulting structures. As anticipated, the observed trends indicate that PEG 
chain length and degree of peptide conjugation are the most important factors in the 
performance of the materials. The unanticipated results that the number of PEG chains 
conjugated to the polymer and the overall polymer length are not important factors in 
modifying the structure of the fibrin fibrils is likely attributable to the existence of a high 
density of polymer chains bound to the protein surface. Circular dichroism measurements 
of fibrinogen with free peptide and with peptide-conjugated polymer demonstrate strong 
interactions with fibrinogen. While the CAERK scramble, used as a control, does bind to 
the solution phase protein, it exhibits a much lower affinity for the protein than CREKA. 
This finding confirms the ability of CREKA to serve as a useful moiety for targeting 
polymers to fibrinogen and fibrin, but suggests that other peptide groups may also be 
useful in controlling the affinity of the polymeric biomaterials for damaged tissues.  
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Figure 7-1  Turbidity analysis. 
 A plot of turbidity (•) versus �
6.52 ×10−27
λ3 � for control sample with no 
polymer. The slope of this graph indicates a fibrin 
masslength  ratio of 2.43 ×1012  Dacm . 
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Figure 7-2  Mass/length ratio from turbidity analysis (controls and PMAA polymers). 
Values (M ± SE) and statistical significance are given: 99% compared to 
no polymer (b) and 95% compared to EPC (g). 
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Figure 7-3  Mass/length ratio from turbidity Analysis (long PEG chain polymers). 
Values (M ± SE) are given. No statistical significance was observed. 
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Figure 7-4  Mass/Length Ratio from Turbidity Analysis (short PEG chain polymers). 
Values (M ± SE) are given. No statistical significance was observed. 
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Figure 7-5  Residual plots for fibrin mass/length ratio (µ). 
The validity of the general linear model used for the ANOVA for the 
fibrin 
masslength  ratio is confirmed by the residual plots. Three outliers are 
observed for P1-L, P3-L, and P4-L. With the exception of these three 
outliers, the linearity of the normal probability plot and random 
distribution observed in the standardized residual plots indicate a lack of 
bias in the model fit. The histogram of standardized residuals indicates a 
normal distribution of residuals. In addition, the vast majority of the 
residuals are within the expected range of ± 2 standard deviations. The 
three outliers with standardized residuals above 3 arise from polymers 
with the lowest level of CREKA conjugation.  
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 Figure 7-6 Main effects plots for fibrin mass/length ratio (µ). 
The main effects plots for the 
masslength  ratio for fibrin provide insight into the 
importance of the various aspects of polymer architecture that were 
investigated. No statistically significant dependence was observed for 
polymer chain length, the number of PEG units, or the number of peptide 
units. Increases in PEG chain length result in a decrease in the observed 
value for µ. The impact of peptide type is unclear; however, the presence 
of peptide units in the polymer appears to result in a larger value for µ.  
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Figure 7-7  Circular dichroism measurements.  
   A comparison of CD spectra for fibrinogen (F), fibrinogen with 0.20 
µg/mL CREKA (F+C (L)), fibrinogen with 1.0 µg/mL CREKA (F+C (H)), 
and fibrinogen with 100 µg/mL P3-H (F+P). The peak at 210 nm 
decreases with increasing CREKA; a similar level of decrease is observed 
with the polymer as with the lower level of CREKA. Both of these peaks 
correspond to a 
CREKAfibrinogen  ratio of approximately 1:1.  
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Table 7-1 Results of Circular Dichroism Measurement 
 
Sample Description 
Molar Ratio of 
Peptide to 
Fibrinogen 
• -Helix Content 
(Percent) 
(M ± SE) 
• -Sheet Content 
(Percent)  
(M ± SE) 
F 100 µg/mL Fibrinogen in PBS 0 32.5 ± 7.0 20.4 ± 5.8 
F + C (L) 
100 µg/mL Fibrinogen + 0.20 
µg/mL CREKA in PBS 
1.1 34.1 ± 2.5 12.4 ± 1.2 
F + S (L) 
100 µg/mL Fibrinogen + 0.20 
µg/mL CAERK in PBS 
1.1 35.3 ± 5.3 16.0 ± 4.5 
F + C (H) 
100 µg/mL Fibrinogen + 1.0 
µg/mL CREKA in PBS 
5.6 35.1 ± 3.8 12.5 ± 1.5 
F + S (H) 
100 µg/mL Fibrinogen + 1.0 
µg/mL CAERK in PBS 
5.6 39.8 ± 0.4 10.2 ± 0.2 
F + P * 
100 µg/mL Fibrinogen + 1.0 
µg/mL P3-H in PBS 
1.0 33.0 12.6 
 
* n = 1 
 
Summary of solutions used for circular dichroism (CD) investigation of fibrinogen 
interactions. Each peptide was studied at 1.1:1 and 5.6:1 molar ratios to fibrinogen. 
CREKA conjugated polymer was studied at a concentration that corresponds to 1 peptide 
unit per protein molecule. With the exception of the polymer (n = 1), each value 
represents the average of 3 – 4 independently prepared samples. 
 
 
 
 
 
 
 
 
Copyright © John M. Medley 2010 
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CHAPTER 8. CONCLUSIONS AND FUTURE STUDIES 
 
In this research, a rational approach for the development of a series of novel 
biomaterials for the prevention of post surgical adhesions has been employed. Starting 
with a thorough understanding of the biochemistry and pathology of PSA formation, 
these materials were developed specifically to meet this significant critical need. Robust 
methodology to synthesize and characterize functionalized block and statistical 
copolymers with precisely controlled molecular architecture has been developed. Initial 
studies, focused on understanding the interaction of non-targeted polymers with 
positively charged model surfaces, verified the viability of this approach and provided a 
critical basis for the development of materials. Subsequent investigations of targeted 
polymers led to an understanding of the relationship between the molecular architecture 
and performance in a number of in vitro tests. The ability of these materials to interact 
with fibrin as a marker of tissue damage and to reduce the propagation of the fibrin gel 
matrix can be modulated by controlling the molecular architecture of the polymers. 
Finally, the results of these experiments were employed to select materials for subsequent 
in vivo experiments to assess their ability to prevent PSA formation in a rabbit model.  
The power of this ground up approach to biomaterial development has been 
validated. The promising preliminary results obtained in these experiments indicate the 
need for additional studies, including the following: 
• The structure-property relationships that have been determined should be 
employed to design and synthesize additional polymers for testing.  
• Investigation of biocompatibility. 
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− Efforts to investigate biocompatibility should begin with an assessment of 
the dose-dependent cytotoxicity of the materials, including the polymers 
of interest and the targeting peptides. These studies should include 
multiple cell types, as these materials will be in contact with many types 
of cells in vivo. 
− Additional biocompatibility tests should include histological investigation 
of the tissues in close proximity to the materials, Ames testing, and LD50 
testing. 
• The fibrin and fibrinogen binding studies that were conducted indicated a strong 
interaction between CREKA and fibrinogen. Additional binding studies are 
warranted in order to develop a better understanding of these interactions.  
− CD can be used to determine the stoichiometry of the interaction between 
the protein and peptide. 
− Complementary techniques, including ITC and SPR, could be used to 
investigate the kinetics and thermodynamics of protein-peptide 
interactions. 
− Additional studies should be conducted to ascertain the precise location of 
the peptide binding sites in fibrinogen. 
• The effect of these materials on fibrin formation has been investigated. In order to 
develop a better understanding of how these materials affect the fibrin gel matrix 
formation, their impact on the rate of fibrinolysis should be evaluated in vitro. 
• Animal studies are needed to assess the in vivo performance of these materials 
compared to existing PSA prevention technologies. 
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• Stability and biodistribution studies. 
− Degradation of the polymers in vitro should be investigated to assess their 
chemical stability. 
− In vivo degradation should be investigated, and the biodistribution of the 
polymer and degradation products should be studied in order to assess the 
likelihood of adverse biological reactions. 
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APPENDIX A. DERIVATION OF RELATIONSHIP BETWEEN FIBRIN 
STRUCTURE AND TURBIDITY 
 
This derivation, originally reported by Carr and Hermans, has been included for 
clarity. Additional details, including the physical justification for the assumptions 
included in the derivation can be found in the literature [230-233].  
 
Turbidity is defined as the total amount of light scattered by a sample. 
Mathematically, this is expressed as Equation A-1: 
 
τ = ∫ 2 πd �iθI0� sinθ dθπ0   (A-1), 
 
where • is the turbidity, d is the distance from the sample to the detector, i•  is the intensity 
of scattered light detected at angle • , and I0 is the intensity of the intensity of the incident 
beam. The ratio of the scattered light to the incident light is described by Equation A-2: 
 
�
iθI0� = Rθ �1+co s2θ�d2   (A-2), 
 
where R• is the Rayleigh scattering ratio and depends on the size and shape of the 
particles causing the scattering. The value of the Rayleigh ratio can be calculated for rod-
shaped particles by Equation A-3: 
 Rθ = Ckλμ4 η sin �θ2�   (A-3). 
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In Equation A-3, C is the concentration of particles in �
gcm3�, •  is the wavelength of the 
incident light, µ is the �
masslength � ratio of the particles in �Daltoncm �, •  is the refractive index of 
the solution, and k is a factor defined by Equation A-4: 
 
k = 2 π2η2�dηdc �2Nλ4    (A-4). 
 
N in Equation A-4 represents Avogadro’s number, while �
dηdc� represents the refractive 
index increment of the solute. Substituting Equations A-2 and A-3 into Equation A-1 
yields the following expression for turbidity: 
 
τ = �πCkλμ2 η � ∫ �1+co s2 θ�(sin θ)sin�θ2�π0 dθ  (A-5). 
 
Integration of Equation A-5 yields Equation A-6: 
 
τ = �44 πCkλμ15 η �    (A-6). 
 
Substituting Equation A-4 into this expression yields Equation A-7: 
 
τ = 88 π3η�dηdc �2Cμ15 Nλ3      (A-7). 
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Values for �
dηdc� and •  can obtained from literature (0.18 𝑐𝑐𝑚𝑚3𝑔𝑔  and 1.333, respectively) 
[230]. Substituting these values, and the fibrinogen concentration of 5.00 × 10−4 gcm 3, 
Equation A-7 simplifies to Equation A-8: 
 
τ = 6.52×10−27
λ3 μ   (A-8). 
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LIST OF ABBREVIATIONS 
 
ABCR Bis-(dimethylamino)methylsilane 
ACN Acetonitrile 
ANOVA Analysis of Variance 
BSA Bovine Serum Albumin 
CAERK Cysteine-Alanine-Glutamic Acid-Arginine-Lysine 
CD Circular Dichroism 
CMC Carboxymethylcellulose 
CREKA Cysteine-Arginine-Glutamic Acid-Lysine-Alanine 
DCC N,N’-Dicyclohexylcarbodiimide 
DCU N,N’-Dicyclohexylurea 
DI Deionized 
DMEM Dubecco’s Modified Eagle Medium 
DNA Deoxyribonucleic Acid 
EDTA Ethylenediaminetetraacetic acid 
EPC Egg Phosphatidylcholine 
FGM Fibrin Gel Matrix 
GPC Gel Permeation Chromatography 
GTP Group Transfer Polymerization 
HA Hyaluronic Acid 
HAc Acetic Acid 
HAx Crosslinked Hyaluronic Acid 
HPLC High Performance Liquid Chromatography 
MA Methacrylic Acid 
MN Number Average Molecular Weight 
MTS 1-Methoxy-1-(trimethylsiloxy)-2-methyl-1-propene 
MW Weight Average Molecular Weight 
NAEM N-Aminoethylmaleimide Trifluoroacetic Acid 
NHS N-Hydroxysuccinimide 
NMR Nuclear Magnetic Resonance 
ORC Oxidized Regenerated Cellulose 
PAA Poly(acrylic acid) 
PAI-1 Plasminogen Activator Inhibitor-1 
PBS Phosphate Buffered Saline 
PD Polydispersity 
PE Polyethylene 
PEG Poly(ethylene glycol) 
PEGMA Poly(ethylene glycol methacrylate) 
PEO Poly(ethylene oxide) 
PLG Poly(L-glutamate) 
PLGA Poly(lactic-co-glycolic acid) 
PLL Poly(L-lysine) 
PMAA Poly(methacrylic acid) 
PMN Polymorphoneutrophils 
PS Polystyrene 
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PSA Post Surgical Adhesion 
PTBMA Poly(t-butyl methacrylate) 
PTFE Poly(tetraflouroethylene) 
PTSA Para-Toluenesulfonic Acid 
QCM Quartz Crystal Microbalance 
QCM Quartz Crystal Microbalance with Dissipation 
rt-PA Recombinant Tissue Plasminogen Activator 
r.t. Retention Time 
RID Refractive Index Detector 
SAM Self-Assembled Monolayer 
SD Standard Deviation 
SE Standard Error 
SPIO Superparamagnetic Iron Oxide 
TBABB tert-Butylammonium bibenzoate 
TBMA tert-Butylmethacrylic acid  
TCP Tissue Culture Polystyrene 
TFA Trifluoroacetic Acid 
THF Tetrahydrofuran 
TMS Trimethylsilyl 
tPA Tissue Plasminogen Activator 
UV Ultraviolet 
VASE Variable Angle Spectroscopic Ellipsometry 
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